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ABSTRACT: 
 
 
Chronic kidney disease (CKD) is described as abnormal kidney function in which one third is 
lost over a period of 3 months and is a global epidemic with a particularly concentrated 
incidence within developing countries, such as Sub-Sahara Africa (SSA). Health facilities in 
SSA are limited due to lack of funding and a dearth in disease and medical knowledge. This 
coupled with the high incidence of both communicable and non-communicable diseases 
makes for an ideal environment for the implementation of Point-of-Care Testing (POCT), 
defined as an analytical test that is performed near the patient, delivering results in real time 
without the need for a conventional laboratory. CKD POCT involves the measurement of 
creatinine in capillary whole blood samples in order to determine the estimated glomerular 
filtration rate (eGFR) of patients in order to stage their CKD status from stage 1-6. 
 
This study aimed to bridge the gap in knowledge with regard to cut-offs of creatinine levels 
and eGFR values when screening a mixed ancestry populations. Currently there is only 
documented and standardized cut-offs for Caucasian and African American populations. This 
study looked at the African mixed ancestry population and acts as a starting point for 
standardizing POCT cut-offs for other international mixed ancestry populations. 
 
103 participants were recruited from the Bellville South community, Cape Town, South Africa. The 
study was a comparative study that was designed to evaluate the Nova Statsensor® point of care 
instrument for the measurement of creatinine for the detection of CKD in adult mixed ancestry 
subjects from the Bellville South Community in South Africa. Secondary objectives included (1) 
the prevalence of CKD based on the results of the instrument, and (2) the correlation between the 
Nova Statsensor®, and the central laboratory creatinine values (IDMS traceable). Ancillary 
objectives of the study were to evaluate the technical quality of POC testing for creatinine in a 
community setting, as well as the evaluation of the cost implications when introducing this form of 
POCT into a primary care setting. 
 
The study found that the Nova Statsensor® in this study had a sensitivity of 66.7% and a 
specificity of 100%, displaying excellent diagnostic accuracy. It was found that the device 
displayed negative proportional bias which may lead to future CKD patients being 
misdiagnosed as healthy within screening programmes. The prevalence was found to be 2.9% 
within this mixed ancestry population. 
 
The device was user friendly and requires a small sample volume, however it is costly to 
implement. 
 
The laboratory evaluation study found that the Nova Statsensor® creatinine meter produced a 
direct creatinine concentration comparison that was less than expected, possibly due to creatinine 
levels depending on several factors which include muscle mass, obesity, gender, and age and 
having a wide reference interval. Thus highlighting the importance of the use of the equations to 
calculate eGFR in CKD screening in order to obtain the CKD staging results which displayed better 
correlation to the reference method, compared to creatinine measurement alone. The device was 
comparable to the reference method when performance was measured based on CKD staging 
through the calculation of the MDRD equation. 
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1.1 INTRODUCTION 
 
Chronic kidney disease (CKD) is a global epidemic with a particularly concentrated incidence within 
developing countries, such as Sub-Sahara Africa (SSA). Health facilities in SSA are limited due to lack 
of funding and limited medical care. This coupled with the high incidence of both communicable and 
non-communicable diseases makes for an ideal environment for the implementation of Point-of-Care 
Testing (POCT). POCT involves devices that range from hand-held to bench top machines that deliver 
test results within minutes, using less invasive sample collection methods and small sample volumes. 
Many of these devices make use of reagents and consumables that can be stored for long periods of 
time at room temperature therefore making them ideal for rural regions. They are relatively easy to 
use and do not require much training. 
 
However current POCT devices’ cut off limits are generally standardized for Caucasian and African 
American peoples. This presents a question with regard to the devices’ accuracy when testing a mixed 
ancestry population, as is found in SSA and South Africa. (NIH: estimating glomerular filtration rate) 
 
1.2 CHRONIC KIDNEY DISEASE 
1.2.1 Background 
Chronic kidney disease is described as abnormal kidney function in which one third of kidney function 
is lost over a period of 3 months (Johnson et al, 2004). CKD consists of 6 stages (Table 1.1) which 
are classified based on the estimated glomerular filtration rate (eGFR). (NHS Horizan Scan Report, 
2014). CKD often goes undetected until it has reached stage 4 or 5. Once stage 5 has been reached, 
the patient enters End-Stage Renal Failure (ESRF) which requires renal dialysis or even a kidney 
transplant, if there is an available donor. These treatments are extremely costly to both the patient and 
state health budgets. It has been estimated that over 1.4 million people worldwide receive renal 
dialysis, and the incidence has been found to be increasing by 8% annually.  
 
Table 1.1: CKD stages and their related eGFR values.  
 
 
 
 
 
 
 
*Usually young adults 
 
CKD is also often linked to several other non-communicable diseases; e.g. diabetes mellitus (Warram 
et al, 1996), hypertension (Schulman et al, 1989), and cardiovascular disease (CVD) (Angelantonio et 
al, 2010). CKD develops in one third of diabetic patients and in one fifth of patients suffering from 
hypertension. It has been estimated that CKD is associated with premature mortality from CVD. The 
risk of death by CVD is increased by 46% in people who have an estimated glomerular filtration rate 
(eGFR) between 30 and 60 mL/min per 1.73 m² (Matsha et al, 2013). These findings were independent 
of traditional cardiovascular risk factors, which include diabetes mellitus and hypertension. (Johnson 
et al, 2004). According to the KDIGO, 2012, hypertension is responsible for over a quarter of the 
world’s rate of kidney failure, and diabetes about one-third of the world’s kidney failure rate.  
 
CKD Stage eGFR (mL/min/1.73m²) Kidney function 
1 >90 Normal or high 
2 60-89 Mildly decreased* 
3a 45-59 Mildly to moderately decreased 
3b 30-44 Moderately to severely decreased 
4 15-29 Severely decreased 
5 <15 Kidney failure 
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In a study conducted by Wali (2010), it was estimated approximately 500 million individuals have CKD 
globally. This translates to 1 in 10 adults globally. CKD is a growing epidemic and is putting financial 
strain on government healthcare systems and developing countries are struggling to cope with this 
burden. In China, over the next decade, the economy will suffer a 558 billion US dollar loss due to 
heart disease and kidney disease deaths and medical treatment. Uruguay is currently experiencing an 
annual cost of 23 million US dollars, 23% of its National Resources Fund budget, just on the treatment 
of dialysis (KDIGO, 2012). 
 
Over 2 million people globally receive dialysis treatment or kidney transplants in order to survive kidney 
disease. Of this 2 million, only 20% are treated in over one hundred developing countries such as: 
South Asia, India, and SSA, compared to the nearly 80% treated in five developed countries: the 
United States, Japan, Germany, Brazil, and Italy (National Kidney Foundation: 
https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease). To put these statistics into 
perspective one must note that the five developed countries only make up 12% of the world’s 
population, whereas the one hundred developing countries make up over 50% of the global population.  
Recent estimates have demonstrated that SSA contributes less than 4000 ESRD dialysis patients to 
the global dialysis population. This is less than 1% of the total global dialysis population (Bamgboye 
2013). This illustrates the poor health care and limited resources within developing countries which 
sadly results in many preventable deaths (KDIGO, 2012). In 112 developing countries, it has been 
found that there are over 1 million deaths annually due to citizens being unable to afford kidney disease 
treatment (KDIGO, 2012). 
 
The exact magnitude of CKD in SSA countries is still poorly characterized, however it is speculated 
that the incidence rates are 3-4 times higher than those in developed countries (Naicker S. 2009). 
Available data on CKD in Africa has been largely derived from hospital-based studies which were 
carried out in tertiary care facilities. There have been very few community-based studies. The reported 
high fatality rate associated with CKD in Africa has been attributed to several factors which include the 
increasing prevalence of communicable diseases such as AIDS, late referrals of CKD sufferers to a 
specialist, poor prognosis, limited renal replacement therapy, and lack of health care workers trained 
in kidney disease prevention (Arogundade & Barsoum. 2008). 
 
Jha et al (2013) found that CKD affects mainly young adults ranging 20-50 years of age, in SSA. The 
main causes being hypertension and glomerular diseases which arise from inadequate treatment due 
to late referral to a health care facility. A noteworthy communicable disease found to be associated 
with nephrology in SSA is Malaria. Malarial (Plasmodium falciparum) nephropathy results in fluid and 
electrolyte disorders, glomerulonephritis, and in some cases acute renal failure (Eiam-Ong S, 2003). 
 
It was also found that SSA greatly lacked renal replacement therapy due to limited availability and 
frightfully high costs. Funding for renal replacement therapy was found to be funded mostly through 
private organisations, with the government contributing minimally and to a very limited number of 
patients. These factors all contribute to the high mortality rate from CKD in SSA. Furthermore, in many 
African countries there is limited or even no access to renal replacement therapy (RRT) and therefore 
again results in many preventable deaths (KDIGO 2012).  
 
Although CKD preventative measures have been implemented in Africa, they are still in their early 
infancy and thus do not have a large enough impact yet to see a decline in CKD prevalence and 
mortality. Another attributing factor is the lack of standardisation of CKD diagnostic tests which are 
currently in use.  
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Screening programs, in areas predetermined to be at high-risk for developing CKD, have been 
introduced to some parts of Africa. These programs involve identifying populations with a high 
prevalence of non-communicable diseases such as diabetes mellitus, cardiovascular disease (CVD), 
and hypertension. Once identified, they are screened for CKD based on their blood creatinine levels 
in order to determine their eGFR. A patient’s urine can also be tested for albumin to determine CKD 
through the Albumin/Creatinine ration (ARC) (Mattix et al, 2002). Elevated levels of urinary albumin 
excretion in patients suffering from diabetes mellitus are an early warning sign that the patient is 
heading towards diabetic nephropathy. Clinically significant nephropathy is diagnosed when a patient 
presents with urinary protein excretion that exceeds 500 mg/24 h (Hutchison et al, 1988). The 
conventional timed urine sample collection for microalbuminuria diagnosis, using the albumin excretion 
rate method, has proved clinically tedious and impractical, due to the incomplete sample collection 
caused by missed void times. This timed method also requires a lot of time input from both the patient 
and doctors involved (Warram et al, 1996). These challenges gave rise to the development of the 
albumin/creatinine ratio (ACR) measurement. This form of measurement involves urine sample 
collection at random void times. It was proposed that screening for microalbuminuria using the ACR 
value of ≥30 μg/mg as abnormal (Warram et al, 1996). The untimed and random sample collection 
method used in the ACR method are advantageous to the patient as the sample is small and can be 
transported in a handbag or pocket making is unnecessary for the patient to remain at the hospital all 
day. This method of collection also makes strict, accurate timed sample collection unnecessary, which 
is much easier for patients to follow (Hutchison et al, 1988). A study conducted by Warram et al (1996) 
found that there was a very close relationship between the ACR method, with random timed collection 
points, and the albumin excretion rate method, with a 3 hour urine collection immediately after a 
random void, having an r² value of 0.94.  From these findings it was concluded that the ACR method 
can be used to diagnose early stages of diabetic nephropathy in diabetic patients (Warram et al, 1996). 
 
Screening for diabetes mellitus involves either the measurement of the HbA1C, also known as glycated 
haemoglobin, or the measurement of the blood glucose levels. Hypertension is simply screened for by 
taking a measurement of the patient’s blood pressure. Screening programs often utilise POCT 
instruments as such areas in Africa often lack conventional laboratories. 
 
If we are to make any significant progress with regard to decreasing the prevalence of CKD and other 
related non-communicable diseases within Africa, we need to make an effort to ensure that both 
patients and health care workers are educated about diabetes mellitus, hypertension, CVD, and CKD. 
This will ensure that they are aware of the signs and symptoms, possible risks, and ways in which to 
manage and even prevent the onset of such diseases (Naicker. 2009).  
 
1.2.2 CKD Symptoms 
During the early stages of CKD many people remain asymptomatic and therefore do not seek medical 
attention until the disease has significantly progressed. CKD presents several non-specific symptoms 
that are not too alarming at first to patients. Several examples include: increased fatigue, decrease in 
appetite and weight-loss, difficulty in concentrating, insomnia, night-time muscle cramping, swollen 
ankles and feet, skin irritation, increased night-time urination, nausea, hypertension, and puffiness 
surrounding their eyes. Many patients only suffer from a few of these symptoms and think nothing of 
it, until the CKD progresses and presents more symptoms which causes concern (Levey et al, 2003). 
 
Patients are also likely to observe blood within their urine. Through the use of a rapid dipstick test 
medical practitioners are able to detect any proteinuria in the urine. The biggest alert to decreased 
kidney function is the presence of albumin within a patient’s urine. (Berns, 2016) 
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1.2.3 CKD Risk Factors 
1.2.3.1 Non-communicable diseases 
i) Diabetes: 
According to the American Diabetes Association (ADA) 2013, diabetes mellitus is “a group 
of metabolic diseases characterized by hyperglycaemia, resulting from defects in insulin 
secretion, insulin action, or both”. 
 
It was found that 9.4 million people in Africa suffer from diabetes mellitus and predicted an 
estimated 140 % increase in diabetic patients by 2025, which translates to 12.7 million 
new cases of diabetes mellitus within Africa alone (Naicker. 2009). The International 
Diabetes Federation stated that in 2015 there were 415 million diabetes mellitus sufferers. 
They projected that this statistic will rise to 642 million sufferers by the year 2040 (Naicker. 
2009).   
 
According to Hjelmesaeth, et al. (2010), obesity and insulin resistance are the two most 
common causes for the development of type 2 diabetes mellitus (T2DM). Muscle plays a 
very important role in controlling the body’s insulin levels as skeletal muscle is the most 
important site of insulin resistance. Skeletal muscle also accounts for glucose disposal 
after infusion. Due to this, it has been found that muscle mass is inversely proportional to 
insulin resistance. Conversely, creatinine is the only metabolite of creatine, which is 
primarily found in striated muscle. Low serum creatinine levels has been linked to an 
increased risk of developing T2DM (Harita et al, 2009). A study conducted by Harita et al 
(2009), which was carried out in non-obese middle aged Japanese males, found this exact 
relationship thus leading to the conclusion that low creatinine levels can also indicate a 
low muscle mass with little risk of developing T2DM, however this was only applied to non-
obese subjects. An obese subject with low muscle mass and subsequently low creatinine 
levels would be considered to be at high risk of developing T2DM (Harita et al, 2009). 
 
Another study conducted by Warram, et al (1996), found that type 1 diabetic patients 
(T1DM) with elevated levels of albumin, within their urine, were most likely to develop 
diabetic nephropathy. 
 
From the above, one can deduce that both T1DM and T2DM patients carry a significant 
risk of developing either chronic kidney disease or end-stage renal failure. Pre-diabetic 
patients can avoid developing kidney disease by modifying their diet and enforcing weight 
loss, if overweight or obese. 
 
The highest prevalence of diabetes is found in those of Indian origin, with the next highest 
being found in black population. Caucasians have been found to have the lowest 
prevalence compared to the above two populations (Mbanya & Ramiaya, 2006) It was 
found that the prevalence of diabetes in black populations followed a westernization 
gradient.  
 
According to the ADA (2013), symptoms of diabetes include polyuria, polydipsia, weight 
loss, and blurred vision. Hypertension nearly always accompanies diabetes. Acute life 
threatening uncontrolled diabetes presents with hyperglycaemia with ketoacidosis in 
T1DM sufferers. Long term complications of diabetes include retinopathy, nephropathy, 
and peripheral and autonomic nephropathy.  
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As previously mentioned, there are two types of diabetes: T1DM and T2DM. T1DM 
involves complete deficiency of insulin production and secretion with β-cell destruction 
(ADA, 2010). Treatment involves intensive exogenous insulin administration with ≥ 3 
injections per day, or insulin pump therapy or continuous sub-cutaneous insulin infusion 
(ADA, 2010). T2DM involves a combination of resistance to insulin action and an 
inadequate insulin secretory compensation response. Treatment entails glycaemic control 
through diet and exercise, or alternatively the addition of oral glucose lowering medication 
such as metformin drugs (ADA, 2010). T2DM does not require exogenous insulin (ADA, 
2013) 
 
According to the ADA 2010 guidelines, diabetes diagnosis involves one of several tests. 
Such tests include the Oral Glucose Tolerance Test (OGTT), ketone measurement, and 
the Fasting Plasma Glucose (FPG) test. Screening for diabetes makes use of HbA1c tests. 
The OGTT is supported by the WHO, but Sacks et al (2002) rejected it as a routine test 
because prominent limitations such as poor reproducibility. WHO supporters, however, 
argue that the OGTT has a higher sensitivity in diagnosis compared to the FPG test.  
The OGTT is currently the gold standard method for diabetes and pre-diabetes 
classification (NHANES OGTT procedures manual, 2007). The OGTT requires a patient 
to fast for 9-hours prior to taking the test. Upon commencement of the test, venous blood 
is first collected then a sugar drink is administered for oral ingestion. After 2 hours another 
venous blood sample is collected in order to examine the body’s response to the ingested 
sugar (NHANES OGTT procedures manual, 2007). The cut-off for diabetes diagnosis is a 
blood plasma glucose level of ≥ 11.1 mmol/L. The 2-hour plasma glucose 75g OGTT 
includes diagnosis of Impaired Glucose Tolerance (IGT) which is diagnosed at a 
concentration range of 7.8 – 11.0 mmol/L. Results within this range is considered too high 
to be normal but too low to be considered as fully diabetic and are thus termed “pre-
diabetic” (ADA, 2013). 
 
There are however several limitations to the OGTT. Such limitations include: uncertainty 
when it comes to patient adherence to the required fasting period, a poor reproducibility 
of the 2-hour glucose tests, the OGTT is time consuming, and there is poor agreement 
between the FPG and 2-hour plasma glucose levels. (Zhou et al, 2010) 
These limitations have paved the way forward for the development and standardization of 
HbA1c testing methods. 
Another form of diabetes diagnosis testing is through the Fasting Plasma Glucose (FPG) 
test which is used to diagnose both diabetic patients and Impaired Fasting Glucose (IFG) 
pre-diabetic patients. Again this involves blood sampling however it does not require 
fasting for the casual FPG cut off limit of 11.1 mmol/L. If fasting was adhered to then the 
FGP cut off limit is lowered to 7.0 mmol/L. IFG is diagnosed when glucose concentrations 
fall within the range of 5.6 – 6.9 mmol/L. 
The above two methods of testing are not reliable for patients suffering from any form of 
abnormal red blood cell (RBC) turnover illness such as haemolytic anaemia. 
 
If any of the above test methods yield positive results, it is required that retesting be carried 
out the following day. If still positive then a sample must be sent in an accredited laboratory 
for confirmatory testing using the gold standard test method, which must also be re-run if 
found positive. However if the patient presents with clinical symptoms such as classic 
glycaemia then re-testing is unnecessary. (ADA, 2010)  
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HbA1c is an additional form of diabetes detection. It is best used as a screening tool and 
method of disease monitoring as it does not suffice as a diagnosis method (ADA, 2010). 
HbA1c measurement reflects an average of glucose levels over a 2-3 month period. 
According to the ADA (2013), HbA1c assays are currently highly standardized with a 
“diagnosis” cut-off of ≥ 6.5%. This established cut-off is associated with the inflection point 
of retinopathy prevalence and has been found to correlate with the FGP and OGTT 
diagnostic cut-offs (ADA, 2010). HbA1c is a quick, minimally invasive “screening 
diagnosis” test which can be self-measured by patients at home. However a legitimate 
diagnosis requires measurement in an accredited laboratory (ADA, 2010) 
 
Diabetes often damages the kidneys and their filtering abilities. High blood glucose levels 
can result in the kidneys filtering too much blood at a time, thus putting the kidney tubules 
under excessive stress. Over time this results in the kidneys leaking extra protein, known 
as albumin, into the urine resulting in microalbuminuria (ADA: Kidney disease – 
Nephropathy). The loss of kidney filtering efficiency also results in a build-up pf waste 
products within the blood. These factors in time cause CKD which then can lead to ESRD. 
(ADA: Kidney disease – Nephropathy) 
 
According to Mbanya and Ramiaya (2010), diagnoses should also take into account the 
presence of other diabetes risk factors. These include: Age, ethnicity, family history, and 
level of physical activity. 
 
ii) Hypertension: 
Hypertension has a negative impact on many organs, primarily the kidneys. Most kidney 
diseases, including CKD, are associated with increased blood pressure. It has been found 
that hypertension directly causes a decrease in kidney filtration and indirectly decreases 
perfusion. These effects result in an increase in creatinine levels, indicative of kidney 
disease. 
 
Hypertension affects the blood vessels, resulting in decreased blood flow, depriving vital 
organs of oxygen. Hypertension damages the kidneys by damaging the nephrons within 
the kidney causing decreased kidney function. As excess fluids and waste products cannot 
be adequately filtered out and excreted the blood pressure further increases (Shulman et 
al, 1989).  
 
According to Jha et al (2013) the global prevalence of hypertension in the year 2000 was 
972 million cases, with most cases being found in developing countries. It has been 
estimated that this figure will rise to 1.56 billion cases by the year 2025. These projections 
have taken into account age-specific and sex-specific adjustments (Jha et al, 2013).  
 
iii) Cardiovascular disease (CVD): 
It has been found that CVD is closely associated with the progression of CKD to end-stage 
renal failure (Vanholder et al, 2005). Patients with any form of kidney dysfunction should 
receive immediate and adequate preventative care against CVD, therefore decreasing the 
chance of cardiac episodes. 
 
Weiner et al (2004) stated that patients receiving dialysis treatment are 10 to 30 times more 
likely to die from CVD events. This study reviewed previous studies and pooled together 
the data in order to determine what risk CKD poses for those at risk of CVD. It was 
speculated that CKD increased the risk of CVD outcomes via several manners; the degree 
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of reduced kidney function can act as an indicator for both duration and severity of other 
CVD contributing factors (for example: hypertension), and also reduced kidney function 
could exacerbate any underlying CVD risk factors such as hypertension and 
cardiomyopathy. 18.4% of the study population were of African American descent with the 
rest being Caucasian. Weiner et al (2004) concluded that CKD was an independent risk 
factor with a hazard ration of 1.19, and there was a significant relationship between kidney 
function and race. African American (black) individuals had a hazard ratio of 1.76 while 
Caucasians (whites) had a hazard ratio of only 1.13. These results suggest that CKD is a 
risk factor all-cause mortality and CVD in the general population, while at the same time 
being a more pronounced risk factor in African Americans rather than Caucasians. 
 
iv) Obesity:  
The prevalence of obesity is rising at an alarming rate in the adult population, but even 
more alarming is the rise of overweight and obese children worldwide. Jha et al (2013) 
found that from the year 2000 there were an estimated 312 million obese adults globally. 
Interestingly enough, it was found that in developing countries there is a steady rise in 
obesity, however this is concentrated in the affluent and educated regions of said 
developing countries.  
 
As previously mentioned, the study conducted by Harita et al (2009) found that there is an 
inversely proportional relationship between muscle mass and insulin resistance. This can 
be related to obesity as a risk factor for CKD because obese people lack healthy levels of 
skeletal muscle and therefore tend to experience increased levels of insulin resistance. 
This leads to T2DM which as previously explained is a major risk factor for developing CKD. 
 
Obesity also often leads to hypertension which can lead to renal damage and subsequent 
development of CKD.  
From the above relationships between CKD and the fore mentioned NCD’s one can 
conclude that obesity is an indirect cause of CKD. This is because obesity results in other 
NCD’s that directly result in the development of CKD. 
 
Adipose tissue is an endocrine organ, highly active, which secretes many factors that aid 
in the development of renal and cardiovascular complications (Ruster & Wolf, 2013). 
 
There are many adipokines which are involved in causing renal injury. These work through 
controlling endothelial dysfunction and inducing oxidative stress and inflammation. 
Adipokines have also been found to be linked to renal anaemia (Ruster & Wolf, 2013). 
There is a delicate balance between the different adipokines, such as protective adipokines 
and those mediating pathophysiological effects. If this balance is disrupted, as caused by 
obesity, renal damage is initiated. Such damage can be contained and in some cases 
reversed by simply a change of lifestyle. One involving exercise and a balanced diet (Ruster 
& Wolf, 2013). Additional options for combating renal inflammation include pharmacological 
agents, and as a last resort; dialysis (Akchurin & Kaskel, 2015). 
 
Akchurin and Kaskel (2015) stated that it has been clearly shown that an inverse 
relationship between eGFR and inflammation exists. However the roles of individual 
cytokines in CKD and ESRD are still being investigated. 
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Most recently, a lot of focus has been placed on the role of adipokines in CKD; specifically 
pro-inflammatory adipokines such as leptin, restin, and the anti-inflammatory adiponectin. 
(Akchurin & Kaskel, 2015) 
 
The NHANES results showed that there is an association between CKD and higher levels 
of leptin and adiponectin. Akchurin and Kaskel (2015) stated that pathophysiology 
inflammation may not be the same in CKD patients of various racial and genetic 
backgrounds. They found that Caucasians have a stronger affiliation of adiposity and 
markers of inflammation when compared against African Americans. 
 
According to Ramos et al (2008) recent studies have indicated that CKD is associated with 
both inflammation and oxidative stress. These factors may also largely contribute to the 
excessive cardiovascular disease as seen in CKD patients. It was also found that Body 
Mass Index (BMI) and body fat percentage were significantly linked with the measured 
markers of inflammation and oxidative stress within the CKD study group (Ramos et al, 
2008). 
 
Mallamaci and Tripepi (2013) stated that there is a significant decline in renal plasma flow 
as body mass increases, excluding obesity with BMIs of > 30 kg/m².  
 
Briffa et al (2013) concluded that when a person is suffering from obesity, there are two 
main cellular points that are linked to proteinuric renal disease: 
i. Structural changes to the glomerulus, therefore allowing more proteins to enter the 
urine. 
ii. The proximal tubules are unable to reabsorb the increased protein load. 
 
Inflammation is generally termed as a response of an organism to any injury; referring to 
any process causing cellular or tissue damage (Vianna et al, 2011). Exacerbated tissue 
damage results in activation of the immune system thus enhancing the inflammatory 
response which facilitates disease onset and progression. For example, CKD with obesity 
or hypertension as the cause of inflammation. Vianna et al (2011) stated that inflammation 
is being more and more recognised as role-player in the pathophysiological process of loss 
of nephron function. 
1.2.3.2 Other 
i) Communicable diseases: HIV and HIVAN 
HIV is an epidemic in SSA and through the screening of the population, it was found that 
in 5-83 % of HIV-infected patients, in this region, showed kidney involvement (Webster et 
al, 2016), however Mallipattu et al (2014) found there is a lack of information regarding the 
SSA population which is troubling as SSA accounts for two-thirds of the global HIV 
population. 
HIV-associated nephropathy (HIVAN) is recognised as a separate condition from HIV itself, 
and in the 1980’s HIVAN was found to be the leading cause of CKD and ESRD in HIV 
infected patients. (Ross and Klotman, 2004) 
HIVAN sufferers display proteinuria within nephrotic range, however they lack signs of 
peripheral oedema. HIVAN patients commonly exhibit no hypertension, which is a unique 
trait in renal disease and HIVAN. Another finding is that HIVAN patients are most often HIV-
seropositive patients who experience a decrease in their ability to store sodium. This 
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coupled with the above HIVAN characteristics suggest that HIVAN is a salt-wasting 
disease. (Ross and Klotman, 2004) 
Ross and Kloman (2004) stated that the only proven reliable test to establish or eliminate 
the presence of HIVAN is a renal biopsy. The presence HIVAN will manifest in the 
glomerular, tubular, and interstitial compartments of the kidney. 
In the study conducted by Ross and Klotman (2004), HIVAN was most commonly 
associated with black ethnicity. This suggests that genetic factors are involved. Mallipattu 
et al (2014) stated that HIVAN is seen most in the genetically susceptible individuals from 
West Africa and not as prominent in the Caucasian population. Jha et al (2013) speculated 
that this is related to the differential prevalence of high-risk alleles in MYH9 and APOL1.  
Early treatment with anti-retroviral (ARV) drugs has been observed to reduce the onset of 
HIV-associated nephrology, however such early use of ARV drugs has been found to carry 
the risk of nephrotoxic effects, thus contradicting the beneficial properties of ARVs. These 
nephrotoxic effects include: electrolyte disorders, tubular toxic effects, interstitial nephritis, 
lactic acidosis, and crystal-induced obstruction (Jha et al, 2013). There is an increasing 
trend of CKD associated ARV nephrology with increasing exposure to atazanavir and 
indinavir (Mocroft et al, 2010). The same study also stated that the use of tenofir within a 
12 month period resulted in a 4-fold increase in CKD incidence amongst Aids patients, 
compared to those who had never been treated with tenofir. In contrast to the above 
information, Szczech et al (2002) found that ARV treatment using protease inhibitor 
treatment resulted in a decrease in the decline of creatinine clearance in clinically 
diagnosed HIVAN patients. These conflicting finding make the benefits of ARV treatment 
for kidney function ambiguous.  
A different treatment option is angiotensin converting enzyme (ACE) inhibitors. Such drugs 
have been demonstrated to prevent or slow the development of renal failure (Ross and 
Klotman, 2004). These finding were supported by a study conducted by Kimmel et al 
(1996). 
Prednisone was also studied as a possible treatment to slow renal failure development in 
HIVAN patients. It was found that creatinine clearance improved while on prednisone, 
however when patients were tapered off treatment they experienced renal relapse (Ross 
and Klotman, 2004). Szczech et al (2002) conducted a retrospective study on 19 patients 
suspected to have HIVAN. The 5 patients that were treated with prednisone experienced a 
clear increase in creatinine clearance by 5.57 mL/min/ month, while the 14 untreated 
patients experienced a creatinine clearance decrease of 3.32 mL/min/month. Therefore 
prednisone is a good treatment for maintaining and improving kidney function, however it 
needs to be a lifelong treatment as tapering off leads to renal relapse.  
Without any of the above treatments, most patients suffering from HIVAN will progress to 
ESRD within 1-4 months of diagnosis, therefore making the mortality of HIVAN a rather 
alarming statistic. (Ross and Klotman, 2004) 
Other specific communicable infections such as the hepatitis B and C viruses, worldwide, 
cause severe kidney lesions leading to nephrology.  
ii) Traditional Medicine: 
The use of certain herbs in traditional medicine, namely in Africa and Asia, has been found 
to have nephrotoxic effects (Luyckx et al, 2005). This occurs when potentially toxic herbs 
are ingested, most commonly through the incorrect substitution of harmless herbs with toxic 
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herbs. Sometimes contamination of harmless herbs occur involving heavy metals or 
interactions between herbal medicine and conventional medicines. Renal injury has been 
reported with association to several herbs. The most common herb associated with CKD is 
aristolochic acid (AA). Ingestion of this herb is associated with progressive interstitial 
nephritis (Jha, 2010). 
iii) Water: 
These include various disorders that directly or indirectly related to water. Water scarcity, 
especially in tropical regions, leads to the risk of dehydration resulting in the accumulation 
of waste products in the blood due to reduced kidney function (Rango et al, 2015).  
Contaminated water may also be harmful to the kidneys during filtration. Harmful 
contaminants include heavy metals and organic compound that can be leached from soil 
(Soderland et al, 2010). Heavy metals include lead, cadmium, arsenic, mercury, and 
uranium. Such heavy metals often lead to exposure through the workplace (Soderland et 
al, 2010). Waterlogged fields and stagnant water often become contaminated with 
waterborne diseases, such as malaria and Escherichia coli, and can damage the kidneys 
(Jha et al, 2013). 
1.2.4 Identifying CKD 
The identification and stage classification is based on the measurement of glomerular filtration rate and 
albuminuria. However calculating the actual glomerular filtration rate by the measurement of urine 
exogenous substances is tedious and impractical. Therefore the eGFR is used, as previously mentioned 
and illustrated in Table 1.1.  This method of measurement is based on the serum creatinine concentration. 
Shimada et al (2016) explains that creatinine is a waste product derived from the breakdown of creatine 
phosphate in the body’s muscle metabolism. Approximately 2 % of the body’s creatine content is 
metabolised into creatinine each day. This results in a daily creatinine production occurring at a relatively 
steady rate.  
The creatinine is therefore a waste product that is freely filtered through the glomeruli of the kidneys. The 
creatinine is also secreted by the proximal tubules of the kidney, however this is in very small amounts. 
(Shimada et al, 2016) 
According to Mohabbati-Kalejahi et al (2012) the first creatinine measurement method was developed in 
1886 by Max Jaffe and was thus name the Jaffe reaction. This method involves a chemical reaction 
between creatinine and picrate in an alkaline solution. This reaction produces an orange-red complex that 
is measured spectrophotometrically and is prone to interferences from certain blood constituents such as 
ketones, bilirubin, certain antibiotics and pyruvate to name a few. This reaction is also sensitive to 
temperature and pH.  
Due to these interferences, there was a need to develop alternate methods of creatinine measurement. 
The enzymatic creatinine assays, with less interference were developed, utilizing enzymatic reactions 
involving either creatininase or creatinine deaminase. (Mohabbati-Kalejahi et al, 2012) 
The last and most accurate method of creatinine measurement, mentioned by Mohabbati-Kalejahi et al 
(2012), is the isotope dilution mass spectrometry. This method is considered to be the Gold Standard of 
creatinine measurement due to it having a very high specificity and accuracy. However this method is 
costly and has a low throughput therefore it is not used as a routine form of testing in most laboratories.  
As previously mentioned eGFR is a calculated value that is used when testing and classifying renal 
function or disease. This method of measurement is quick and practical when applied to settings such as 
local clinics where many patients are attended to daily. eGFR is and estimation equation, used to calculate 
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the GRF incorporating the result from a serum creatinine test, gender, age, body size, and race. This quick 
form of measurement is useful in the staging of kidney disease, such as CKD, as well as in formulating a 
treatment plan based on the severity of decreased eGFR. (NKF: Creatinine: What is it? – 
https:/www.kidney.org/atoz/content/what-creatinine) 
Several estimation equations exist. The equations mostly used are the “Modification of Diet in Renal 
Disease” (MDRD) equation and the “Chronic Kidney Disease Epidemiology Collaboration” (CKD-EPI) 
creatinine equation.  
Existing equations need to be reviewed for accurate assessment of the differences involved by ethnic 
origin, region, or possibly both in order to validate said equations for obtained eGFR values, as per 
ethnicity, against the reference method eGFR values. Until this has been achieved, it is advised that the 
modified MDRD or CKD-EPI equation be used with acknowledgment of the possible occurrence of 
variation in results thus leading to misclassification of CKD. It is for this reason that POCT creatinine 
devices based on eGFR measurement are used as screening tools and not diagnostic tools. (Jha et al, 
2013)  
1.2.5 Creatinine levels as a measure of CKD 
Serum creatinine remain the most common biochemical parameter to determine the eGFR and assess 
kidney function. Creatinine is formed in the muscle at a relatively constant rate through the dehydration of 
creatine. The conversion is irreversible therefore making it a viable marker to measure. The amount of 
creatinine formed per day is directly related to one’s muscle mass, which of course varies between gender, 
age, and ethnicity. (NKF: Creatinine: What is it?) 
The creatinine compound is freely filtered through the kidneys’ glomeruli, without being appreciably 
reabsorbed or secreted by the kidney tubules. This results in the serum creatinine concentration forming 
a balance between its production and the GFR. Therefore, if the GFR decreases, while creatinine 
formation remains constant, the serum creatinine levels will rise. Creatinine levels are used to calculate 
the eGFR, and even though the eGFR has several limitations, it is able to detect reduced GFR at relatively 
early stages of kidney disease. This makes it an extremely useful tool in CKD screening.  
 
 
1.2.6 Estimated Glomerular Filtration Rate 
The GFR refers to the measurement of how well the kidneys are filtering waste products from the blood 
stream. GFR has been found to be the best overall measure of kidney function. The gold standard for 
measuring GFR involves administering inulin, a group of naturally occurring polysaccharides, and 
subsequently measuring its clearance. This is however not routinely done as it tedious and expensive. 
Therefore specialized equations have been developed, namely the MDRD equation which takes into 
account age, gender, and ethnicity, in order to obtain an eGFR value. (Botev et al, 2009) 
i. MDRD and Cockcroft-Gault equations: 
eGFR is determined through either of the following two equations: the Modification of Diet 
in Renal Disease (MDRD) equation or the Cockcroft-Gault (CG) equation. A review study 
conducted by Zhang et al (2008) found that the MDRD equation was reported as more 
accurate in determining CKD status in elderly patients, 65 years and above, whereas the 
CG equation overestimated eGFR values.  
Levey et al (2005) reported that the MDRD equation performed substantially better in 
estimation of eGFR in people with diagnosed CKD and with people who had an eGFR of 
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<90 mL/min/1.73m² compared to that of the CG equation. An additional draw-back of the 
CG equation is that it does not consider ethnicity. This makes the MDRD equation the most 
clinically favoured equation when estimating eGFR. Levey et al (2005) suggest that the 
additional use of novel, emerging biomarkers such as cystatin C are important factors to 
study in order to improve upon the estimation of eGFR across genders, ages, and ethnicity. 
 
The MDRD equation was introduced in 1999 (Ali et al, 2013). Rostoker et al (2009) stated 
that the MDRD equation was first developed in a population of patients with severe renal 
function impairment. The CG equation was previously introduced in 1976 (Rostoker et al, 
2009) and was previously developed in a group of 236 Canadians, mostly male (Noble & 
Johnson, 2007).  
Inulin and isotope measurement methods are used as the gold standard method in 
validating the accuracy of eGFR determination by MDRD and CG equations (Ali et al, 2013) 
The MDRD equation predicts eGFR and is as follows: 
eGFR = 186 𝑥 (𝑆𝐶𝑟)−1.154 𝑥 (𝐴𝑔𝑒)−0.203 𝑥 0.742 (𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒)𝑥 1.212 (𝑖𝑓 𝑏𝑙𝑎𝑐𝑘)  
(Munikrishnappa, 2009) 
 
Munikrishnappa (2009) stated that the MDRD equation has been found to be less accurate 
at eGFR levels above 60 mL/min/1.73m² compared to the CG equation. This finding was 
also supported by Ali et al (2013). This equation also performs significantly poorer in 
subjects without renal disease (Lin et al, 2003). Lin et al (2003) found that the MDRD 
equation exhibited less bias than the CG equation, and was also more precise in general. 
However the MDRD equation gave results with a smaller median absolute error compared 
to the CG equation, as stated by Rostoker et al (2009). Lin et al (2003) stated that the 
MDRD equation has been extensively evaluated in both Caucasian and African American 
populations and makes adjustments for these two ethnic groups. 
 
The CG equation predicts creatinine clearance (CrCl) in place of eGFR and is as follows: 
CrCl (mL/min) = 
[(140−𝐴𝑔𝑒 𝑖𝑛 𝑦𝑒𝑎𝑟𝑠)𝑥 𝑊𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑔]
𝑆𝑐𝑟 (𝑚𝑔/𝑑𝐿)
 𝑥 72 𝑥 0.85 (𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) 
(Munikrishnappa, 2009) 
 
CrCl generally overestimates eGFR thus making the CG equation a slight overestimation 
itself (Muniskrishnappa 2009). However, studies have shown that the CG equation 
underestimates eGFR in elderly patients, especially at higher eGFR values (Lee et al, 
2009). eGFR values calculated by the MDRD and CG equations were the same in subjects 
with an eGFR < 30 ml/min/1.73m², but the CG eGFR was higher than that of the MDRD 
eGFR in subjects younger than 50 years of age and lower in subjects older than 60 years 
of age (Lee et al, 2009). These differences increased with age. 
 
Differences between the two equations are as follows; the CG equation can be corrected 
for using body surface areas while the MDRD equation corrects for race.The CG equation 
measures CrCl while the MDRD equations measures eGFR directly. 
Similarities between the two equations include; both equations take into account gender. 
Both equations can be used interchangeably at CKD stages 1 and 4 (Ali et al, 2013) 
 
One of the several limitations of the eGFR is that it is not suited to all clinical situations, 
for example: it is not ideal for paediatric (<18 years) and elderly patients, pregnant 
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women, patients with skeletal muscle disease, and patients with rapidly fluctuating kidney 
function. (Kidney Health Australia: Chronic Kidney Disease (CKD) and eGFR) 
The Modification of Diet in Renal Disease (MDRD) equation is the most widespread used 
equation for calculating eGFR. This equation was designed to register a decrease in 
GFR, however it does not work well when it comes to values above 60 mL/min/1.73m². 
Therefore results above this value are reported as >60 mL/min/1.73m². A more accurate 
and concise test for detecting reduced GFR involves a 24 hour urine test in which 24 hour 
creatinine clearance is monitored where both the urine and serum creatinine levels are 
measured. This test is uncomfortable and tedious and therefore is mostly used in drug 
dosing (Horowitz et al, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
15 
 
Table 1.2: Limitations and advantages of the MDRD and CG equations (adapted from 
Munikrishnappa, 2009). 
Equation Limitation Advantage 
Both MDRD and CG  Renal and extra-renal 
conditions affecting 
steady state of 
creatinine in plasma 
 Interference with 
creatinine assay 
 Variation is muscle 
mass and diet 
 Take into account 
gender 
MDRD  Reliability and 
accuracy decreased 
in eGFR extremes 
 Lack of validation in 
some ethnic groups 
 Equation not adapted 
for drug dosing for 
renal impairment 
patients 
 Requires a computer 
for data processing 
 Takes into account 
race ethnicity 
CG  Calibration bias 
 Values that are not 
adjusted for body 
surface area 
 Improved accuracy 
in elderly patients 
 No computer 
required, results can 
be calculated at 
bedside 
 
ii. Ethnicity and eGFR: 
According to Xue et al (2007), people of African American descent and several other 
minority ethnic groups are more prone to developing end-stage renal disease (ESRD) and 
CKD compared to that of Caucasian people. However research is only able to partially 
explain this phenomenon. The study found that the other minority groups were prone to 
CKD and ESRD even when analyses were adjusted for age and gender. This result was 
also found regardless of the participants’ diabetes and hypertension statuses. This finding 
suggests that diabetes and hypertension are not a factoring influencing ethnic differences 
in development of CKD and ESRD when compared to Caucasians.  
 
The study also found that socioeconomic status, access to health care, and co-morbid 
conditions did not contribute to the minorities developing CKD and ESRD. This finding was 
stated to be supported by several other studies, including those conducted by Hall et al 
(2004) and Hsu et al (2003).  
Interestingly enough, the study by Xue et al (2007) found that although the incidence of 
ESRD and CKD was higher in the Black population, their mortality rate was lower than that 
of the Caucasian population. It was suggested that this could be explained by Black 
patients starting RRT earlier than that of White patients. 
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This study also discussed that a possible reason for the higher incidence of CKD and ESRD 
within the Black population is due to CKD being diagnosed based on eGFR values obtained 
through the measurement of creatinine levels. This is an important factor in racial 
differences in CKD incidences because it has been found, and supported by other studies 
(Obrador et al, 1999), that physiologically the Black population have naturally higher serum 
creatinine levels than that of Caucasian people. Although eGFR is not the sole criterion for 
diagnosing CKD, it is a very important factor. Therefore this could possibly explain the racial 
differences in CKD and ESRD incidence rates.  
 
With regard to the above study, one can assume that physiological differences between 
races should be further studied in order to ascertain what other possible differences, apart 
for serum creatinine levels, could be contributing to this difference in incidence rates. 
 
A study performed in a black South African population has concluded that the 4-variable 
MDRD equation can be used without the ethnicity correction factor of 1.212. This however 
cannot be generalised to all black population within South Africa because of racial diversity 
within the South African black population (Van Deventer H, et al. 2008). 
1.2.6.1 Standardization of eGFR equations 
According to Earley et al (2012) there are 5 criteria that need to be met when developing, validating, and 
standardizing GFR estimation equations:  
1.2.6.1.1 The equation should be developed and validated in separate populations, and both 
populations should represent the intended population. There should be a large enough 
sample size in order to detect a significant improvement in the equation’s performance.  
1.2.6.1.2 The measured GFR should be based on either urine or plasma clearance of an exogenous 
filtration marker.  
1.2.6.1.3 The serum creatinine assay used in the development and validation data sets should be 
standardized against standard reference material, such as IDMS traceability.  
1.2.6.1.4 Measurements of the equation should include precision, bias, and accuracy. 
1.2.6.1.5 Validation must include the comparison of another newly developed equation with more than, 
or equal to one previously developed equation within the population of interest in order to 
determine which equation is superior. A good comparison to use is the unmodified CKD-EPI 
equation (Earley et al, 2012) 
1.2.7 Albuminuria 
Albumin is a fairly large protein produced by the liver and which is used to regulate colloid osmotic pressure 
(COP) within the body (Nicholson et al, 2000). Albuminuria (previously known as microalbuminuria) is a 
condition in which small amounts of albumin have entered the urine. When proteins are lost through urine, 
it results in a decrease in COP and thus results in an increase of filtration across the capillaries. This leads 
to an accumulation of fluid within the bodily tissues, which can lead to pulmonary oedema (Nicholson et 
al, 2000). 
Measurement of albuminuria is an easy method to test for kidney damage. This is because larger 
molecules such as proteins are important for the body and thus do not filter through the kidneys for 
excretion. The reason for albumin being an easy marker for kidney damage is because it is one of the first 
proteins to enter the urine when there is kidney damage. (NKF KDOQI Guidelines: 
https://www2.kidney.org/professionals/KDOQI/guideline_diabetes/guide1.html) 
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The American Diabetes Association (ADA) states that the gold standard test for measuring urine albumin 
clearance is a 24 hour urine measurement, however this method of measurement is tedious and time 
consuming. It is also open to possible errors in collection methods and sample storage. A newer and more 
convenient method of measurement is the spot urine albumin/creatinine ratio (ACR). This spot urine must 
be collected under standardized conditions, which are stipulated to be the first voided and midstream urine 
specimen, in order to detect microalbuminuria. The ADA and National Kidney Foundation (NKF) define 
albuminuria when a patient has an ACR between 30 and 300 µg/mg for both male and female. However 
this definition does not take into account gender differences in creatinine excretion (Mattix et al, 2002). 
Derhaschnig et al (2002) stated that it is unclear if the measurement of albuminuria alone is enough to 
advocate kidney damage, or if it is necessary to combine this measurement with an ACR test. Both 
methods of measurement can be conducted on the same spot urine sample, making it convenient to 
conduct both tests instead of just one of the two. It would be preferable to conduct both tests when testing 
for CKD because the ACR test includes the creatinine component of kidney filtration which is the main 
marker in determining CKD status. 
Through the results obtained from creatinine eGFR measurement, albuminuria measurement, blood 
pressure, and blood sugar measurements medical practitioners are able to make a reliable and accurate 
diagnosis of a patient’s kidney health status. 
1.2.8 Treatment for CKD: Prevention and Screening 
The NKF recognised the important role which family physicians play in detecting and managing CKD in 
patients, especially with patients in early stages of CKD where medical intervention is most effective. 
Therefore the NKF set out to develop guidelines for physicians to follow in order to manage CKD patients. 
(NKF Fast Facts Sheet: https://www.kidney.org/news/newsroom/factsheets/FastFacts) 
CKD often goes undetected until stage 4 is reached. This is due to the fact that stages 1-3 progression is 
slow and asymptomatic. This creates a need for patients deemed “at increased risk” to be screened and 
monitored for CKD development and/or progression. Patients deemed to be “at increased risk” are those 
who already suffer from diabetes and/or hypertension. Patients suffering from afore mentioned conditions 
can be managed by controlling and treating their pre-existing conditions, the onset of CKD could be slowed 
or even possibly prevented. (Johnson et al, 2004) 
When a patient, without any pre-existing conditions, is diagnosed with CKD it is advisable to start 
aggressive treatment against hypertension and cardiovascular disease. This is because these conditions 
have been found to develop during CKD progression and also increase the rate of CKD progression. 
Preventing these complications from arising can result in a decreased mortality rate.  
CKD treatment can also involve changing the patient’s diet, lifestyle, and medication. A new diet should 
be followed which consists of reducing the intake of sugar, sodium (which will help decrease blood 
pressure), cholesterol (which will prevent heart and blood vessel disease), and control the intake of 
carbohydrates which are converted into sugars upon metabolism.  A well-studied and popular diet is a 
protein restricted diet that still provides adequate amounts of amino acids and energy (Bellizi et al, 
2016). 
Lifestyle changes should involve weight management, limited alcohol intake, regular exercise, and 
patients who smoke must quit smoking. Medications to aid in managing CKD include angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers, both of which protect the kidney and 
lower the risk of cardiovascular disease and diabetes mellitus. (NKF Fact Sheet: www.kidney.org). 
Once a patient has reached stage 4 of CKD, treatment involves controlling pre-existing and resultant 
conditions as well as preparation for renal replacement therapy, being either dialysis or kidney 
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transplantation. (Johnson et al, 2004). Any medication taken by the patient should have its dose re-
evaluated and altered due to decreased kidney function.  
By the time a patient has reached stage 5 of CKD, they have end-stage renal failure. The only treatment 
is to continue renal replacement therapy. Renal failure cannot be cured and thus the best treatment for it 
is prevention (Johnson et al, 2004). 
 i) Prevention 
There are many treatment plans that can slow the progression of CKD as well as reducing the risk 
of CVD mortality. The most common treatment plans involve the management of blood pressure, 
by use of medication that inhibits the renin-angiotensin pathway, glycaemic control through diet 
modification, and lipid-lowering therapy, regardless of the patients starting concentration of 
cholesterol. (Jha et al, 2013) 
Lipid-lowering therapy reduces the chances of an atherosclerotic event occurring in patients 
suffering from CKD. Prevention of further deterioration of impaired kidney function is also very 
important. This will include optimizing the salt and protein intake of a patient with CKD. This will 
aid is controlling blood pressure and prevent excess proteinuria (Jha et al, 2013).  
The last effective measure of preventative treatment is self-management, which involves improving 
one’s lifestyle, diet, adherence to treatment, as well as their knowledge of their disease. Self-
management is a cost-effective manner of treatment for patients suffering from stage 3 CKD. 
According to Jha et al (2013) this is being investigated in a randomised trial.  
ii) Screening 
Cost-effectiveness of screening the general population for CKD is still unclear. Screening for CKD 
using eGFR to identify patients who will benefit most is poorly characterized and investigated. Most 
population-based screening approaches have been implemented in developed countries, however 
due to the population variations of risk factors, one cannot screen all ethnic populations based on 
the same risk factors as this will lead to the possibility of some groups’ CKD status being 
misclassified. However population based screening for the relevant risk factors, such as HIV, 
diabetes, hypertension, and CVD in SSA, may have the advantage of increasing health awareness 
is developing countries and aid in educating the population with regard to the risks involved in 
developing such diseases. If the population is more aware of the risks that such diseases pose to 
their health and well-being, it may lead to the public taking an interest in their diet and lifestyle and 
thus may reduce the disease burden on the country’s health care system and budget. (Jha et al, 
2013) 
 
1.3 POINT-OF-CARE TESTING 
1.3.1 Introduction 
Point of Care Testing (POCT) is defined as an analytical test that is performed near the patient, delivering 
results in real time without the need for a conventional laboratory. Such tests can be carried out at the 
patient’s bedside in hospital or in the consultation room of a local clinic. Other possible locations include 
ambulances, and all sectors of a hospital (ICU, theatre, surgical wards, and consultation rooms).  
(Tirimacco, 2013) 
POCT instruments can be handheld devices, desktop analysers, or even non-instrumental which would 
make use of, for example, reagent strips instead of a machine. (Tirimacco, 2013) 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
POCT is a promising form of medical screening which allows for large populations of people to be 
screened for possible diseases, such as diabetes mellitus. It eliminates the waiting period for the return of 
conventional laboratory results, which in turn may lead to increased clinical performance with regard to 
the number of patients attended to per day. POCT also allows for smaller less invasive sample collection, 
however these benefits can only be optimally achieved if cooperation with the central laboratory is 
achieved. (POCT Implementation Guide: 2008) 
 Some POC instruments can be used by patients in the comfort of their own home, such as a glucose 
meter, thus resulting in patients taking a greater responsibility for their own health. 
There are however several disadvantages which include; the possibility of inaccurate use of the instrument 
resulting in inaccurate results. This could lead to the need for additional testing, and thus increased 
consultation time and waiting period. Poor record keeping of the quality controls (QC) and the quality of 
results is also a concern. As well as the linearity of the POCT results compared with those of a conventional 
laboratory. (POCT Implementation Guide: 2008) 
If POCT instruments could be evaluated and validated, proving that they are as accurate in their results 
as those obtained from conventional laboratories, then POCT has great potential in changing the 
conventional patient diagnosis procedure for diseases such as diabetes mellitus, chronic kidney disease, 
and cardiovascular disease. 
POCT can also be the solution to many health care issues in developing countries. This can be seen in 
the significant reduction in unnecessary anti-malaria treatment during the last decade, through the use of 
POCT. This highlights the transforming potential of POCT for futures to come. However there will always 
be a need for central laboratories as they offer qualified clinicians and physicians who can provide 
consultation and guidance when it comes to result interpretation. These laboratory personnel can identify 
any pre-analytical and post-analytical errors, recommend follow up tests if POCT yields worrisome results, 
and also act as POCT coordinators of quality management.  
POCT has also been defined as a “disruptive innovation” (Luppa et al, 2016) that is a sustaining 
technology, with the potential to provide healthcare with innovative performance metrics. 
Limitations for further evolution of POCT come in several forms, namely: the establishment of new and 
reliable parameters, finances where institutions cannot financially keep up with the technological 
equipment advancements, as well as institutions being unable to keep up with the evolving changes in 
clinical diagnostic methods due to technological advances, and finally: POCT evolution and advancement 
is often hindered through the market failure of non-invasive devices which have been in the developmental 
pipeline for several decades before being cancelled (Luppa et al, 2016). 
 1.3.2 Methods of sampling and sample sources (Luppa et al, 2016) 
 Invasive: whole blood samples (venous/arterial) 
 Moderately invasive: capillary blood 
 Non-invasive, but sampled: urine, saliva, tears, sweat, faeces, sputum, etc. 
 Non-invasive and not sampled: direct detection methods applied to the skin surface/plane 
(electroporation, optical techniques, temperature measurement). 
1.3.3 Diabetes in Sub-Saharan Africa and the importance of POCT assessment 
SSA is familiar with wars, malnutrition, and communicable diseases; subsequently focus has been on 
emergency response services, food care packages, as well as communicable disease prevention. This 
has left non-communicable diseases unaddressed in most parts of SSA. This is a common occurrence 
even though the non-communicable diseases are responsible for a large share of disease burden and 
have been dubbed as “The Silent Killer” (Renzaho, 2015). Diabetes mellitus is the biggest silent killer and 
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was previously considered to be rare in rural African regions. This has changed over the last several 
decades and diabetes has been found to be a severe burden in SSA. 
The rising incidences of diabetes in SSA regions are most prominent in urbanized areas. Mbanya et al 
(2010) stated that the estimated growth and urbanization of SSA will increase from 12.1 million in 2010 to 
23.9 million by 2030. This shift of urbanization has resulted in the SSA traditional diet, which is high in 
fibre, low in fat and salt, to be replaced by a more westernized diet. Westernized diets are energy dense, 
highly refined, and have a high salt and fat content. The urbanized life style is also more sedentary and 
thus results in a decrease in physical activity (Renzaho, 2015). The above can account for higher diabetes 
incidence rates within urban regions compared to those of rural regions. Risk factors associated with the 
westernized diet and a more sedentary lifestyle include increased body-mass index, waist circumference, 
waist-to-hip ratio, and total body obesity. It is challenging to get high risk patients to lose weight and 
improve their eating habits as it is a common cultural belief that obesity is a sign of affluence. This belief 
has been instilled through the persisting poverty and destitution within SSA, thus making inhabitants 
reluctant to shed excess weight. (Mbanya et al, 2010) 
In several SSA screening studies it was found that less than 50% of the participants were aware of their 
diabetic status, where as in South Africa more than 50% of the participants knew what their status was. 
This could be explained by South Africa having better and more easily accessible health care facilities, 
compared to those in SSA (Mbanya et al, 2010). In SSA, serious challenges faced by diabetic patients 
include the lack of constant access to antidiabetic drugs, namely insulin. In addition to this, such drugs are 
not easily affordable. This makes diabetes management almost impossible and thus the resulting 
incidence rates lead to an increase in morbidity and pre-mature mortality. This in turn reflects heavily on 
the government and health care system in the form of additional socioeconomic costs. 
Mbanya et al (2010) stated that the prevalence of diabetes increases with age, starting from the age of 55 
years old (Mortala et al, 2008). It was also stated that sex was not a contributing factor as it had little effect 
on diabetes in SSA. Another contributing factor to the increasing prevalence of diabetes in SSA is the 
chronic burden of communicable diseases, namely tuberculosis (TB) and HIV. It has been found that 
patients receiving anti-retro viral (ARV) medicines have an increased prevalence of diabetes. This could 
be explained through the metabolic pathways that are affected by highly active anti-retroviral therapy 
(HAART), which include the direct effects of HAART, the pro-inflammatory process of HIV, and also the 
indirect effects of HAART which includes a change in body fat distribution. TB results in an increased risk 
of diabetes due to an increased risk of pancreatitis and insulin deficiency. TB also complicates diabetes 
management (Renzaho, 2015). 
Most SSA countries’ abilities to respond effectively to the diabetes epidemic is greatly hindered by the lack 
of funding. If the countries could implement mass screening programs, then diabetic sufferers could be 
identified earlier and thus managed easier. The screening programs would also be able to identify those 
at high risk and thus allow for early implementation of measures to prevent the progression of the disease. 
POCT would be an ideal form of mass screening as the devices are small, robust, and have quick analysis 
time. If such devices could be placed in local clinics then more people could be screened instead of just 
those visiting the far and few between hospitals. 
Another interesting finding by Renzaho (2015) was that most SSA inhabitants rely on traditional healers 
for medical attention. This could be useful as most traditional healers have embraced biomedical 
technologies and thus would possibly consider being trained in POCT. This would open up diabetes 
screening to a much larger population. If found to have diabetes or be at risk then the traditional healer 
could refer the patient to medical practitioner for further treatment and management. 
If none of the above issues are addressed, SSA may be facing a new epidemic as large, if not larger, than 
the HIV epidemic.  
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1.3.4 Current POCT Analytical Devices (Luppa et al, 2016) 
Currently there are several popular methods of POCT available today such as complex biosensor-
based devices, test strips, lateral-flow tests, benchtop POCT analysers, and Lab-on-chip (LOC) 
devices. 
The Novastatsensor® makes use of the complex biosensor-based method: 
Miniaturised biosensor systems have been developed in the last two decades, and can detect 
analytes by applying two forms of detector components: biological and physiochemical. Biological 
fluids such as whole blood, salvia, serum, plasma, urine etc. contain components that interact with 
the biological components on the recognition layer, which is fixed on the solid-state surface of the 
sensor inside of the device. At the transducer surface, biospecific reactions are read out through 
the use of either optical, microgravitational, or electrochemical methods.  
1.3.5 Current POCT Analytical Techniques (Luppa et al, 2016) 
Through the miniaturisation of electronics and optics, portable devices have been developed which, when 
having completed stringent validation studies, can produce results that are aligned with results obtained 
from main central clinical laboratories. These miniaturized analytical techniques are based on mostly 
electrochemical methods, optical transduction, and chromatography. Currently the electrochemical and 
optical techniques are most favoured, these include: electrochemical based devices, optical based 
devices, and mass-sensitive based devices. 
1.3.6 Emerging next-generation POCT 
POCT is estimated to rise in countries with large populations, the latter resulting in an increase in the 
prevalence of infectious and chronic diseases. This leads to a need for POCT devices that are affordable, 
robust, and unrefrigerated in order to provide optimal sensitivity and specificity, while involving minimal 
steps and rapid turn-around time (Vashist et al. 2015). The development of these technologies would be 
well suited for rural regions such as those found in SSA where storage facilities and medical funding are 
limited and patients do not have  the means to make multiple trips to clinics, therefore making this form of 
up and coming technology relevant to all POCT research and development. 
1.3.6.1 Strategies for Prolonged Reagent Storage and Shelf Life 
The most common strategies entail the use of sugars, sugar alcohols or stabilizers, reagent pouches, 
freeze drying, or encapsulation of biomolecules within natural polysaccharides. One example is a non-
ionic natural polysaccharide, called pullulan, which forms an oxygen-impermeable solid when dried. This 
allows for storage of unstable biomolecules as stable water-soluble pellets, lasting several months at room 
temperature. This is particularly useful in developing countries’ rural regions where adequate electricity 
and refrigeration is lacking. (Vashist et al. 2015) 
1.3.6.2 Challenges 
There are still many challenges facing the development of POCT devices. The number one concern and 
challenge is device demonstration of high analytical precision and reproducibility for analyte quantification 
when large numbers of patient samples are involved. This needs to be done with minimal or zero 
interference by potential nonspecific substances. (Vashist et al. 2015) 
The integration of microfluidic systems with POCT has proved to be challenging due to the difficulties 
faced in the miniaturization of components that are required for the active transport of liquids. Additionally 
there is the challenge of reagent long-term storage and usage. (Warade, 2014) 
Stellenbosch University  https://scholar.sun.ac.za
22 
 
In the case of the previously discussed CP-based POCT, there is the concern with regard to hygiene and 
proper disposal of contaminated objects, such as test strips or cartridges. These issues need to be 
resolved before CP-based POCT devices can be released to the public for private self-monitoring 
(Warade, 2014). 
Due to the dynamic and ever increasing use of the internet and electronic communication devices, there 
is major cause for concern when it comes to patient record confidentiality, security, and ownership. Patient 
information needs to be secured behind advanced encryptions and algorithms which can prove costly to 
develop and implement.  In addition to this problem, there is the obstacle of creating user platforms and 
interfaces in order to allow for patients to access their data. As well as a bidirectional communication 
between the POCT devices and said user platforms and interfaces. Currently password and usernames 
are implemented as a form of ensured privacy and security. (Vashist et al. 2015) 
The last and equally important challenge to overcome is the economic feasibility, which is a major 
determinant when it comes to commercialization of POCT devices. Complex instrumentation and reagent 
or cartridges result in the need for extensive, and often costly, training of health care personnel. Test 
strips, such as urine dip sticks, are a good example of economic feasibility as they are cheaper than most 
other POCT devices, they also require only basic training and are extremely simple to use. This highlights 
the need for the development of cheap and user friendly methods for POCT. (Warade, 2014) 
An often overlooked factor to consider is the involvement of private medical insurance companies as the 
cost implications of POCT may affect patients’ reimbursement policy and monthly premiums. This leads 
to the dire need for the involvement of the industry sector in the early critical stages of POCT device 
commercial development. (Vashist et al. 2015) 
1.3.7 POCT Operator Training and POCT Management 
Often the POCT operator has no background training in laboratory medicine, even when used in 
professional medical environments. For example: patients conducting self-monitoring from home, or 
nurses in hospitals and clinics. This largely results in errors occurring in POCT due to operator error 
instead of device related failure. The most commonly found errors include: operators failing to carry out 
basic (1) device preparation, (2) maintenance and QC steps, (3) non-adherence to standard test 
procedures, and (4) the use of expired reagents. This emphasises the need for the implementation of 
numerous guidelines and policies that call for the formal training of POCT operators in order to reduce 
these avoidable errors. (Luppa et al, 2016) 
The International Standards Organisation (ISO) established the compulsory guidelines for ensuring a 
universal quality control standards and competence worldwide.  
ISO 22870:2006 was implemented based on ISO 15189 and has been updated to ISO 22870:2016 ((ISO 
website: http://www.iso.org/iso/home/store/catalogue_tc/catalogue_detail.htm?csnumber=71119), with 
special emphasis placed on POCT.  
The principle of ISO 22870:2016 puts emphasis on operators’ qualifications using requirements for quality 
and competency (ISO website: https://www.iso.org/obp/ui/#iso:std:iso:22870:ed-2:v1:en). It also 
emphasises the appointment of a manager for the practical and theoretical training of POCT operators 
before being declared qualified for POCT (Luppa et al, 2016). It includes the appointment of a quality 
manager who is responsible for the design, implementation, and operation of quality control that will ensure 
the POCT conforms to the quality standards of the central laboratory. ISO 22870:2006 also places 
emphasis on Internal Quality Control (IQC) and External Quality Control (EQC). These guideline 
implementations are applicable to both hospital environments and outpatient clinics, only excluding home 
care usage. 
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1.3.8 Quality Assurance and Risk Management 
In addition to the afore mentioned standard regulatory requirements, many more guidelines and 
recommendations have been put forward by several accredited bodies, such as Clinical and Laboratory 
Standards Institute (CLSI) and other national accreditation bodies, on how to manage POCT; especially 
through the use of Internal Quality Control (IQC). (CLSI webpage: http://clsi.org/) 
IQC procedures monitor the results that are being measured in order to determine if the POCT device is 
within the predetermined and acceptable ranges of the QC reagents. Such quality control is ensured 
through the implementation of internal and external audits of current POCT (Pernet, P. 2014).  
Many POCT devices make use of small disposable testing units, thus the performance of a single test 
cannot provide information on further accuracy, unlike central laboratories’ batch-based processing. In 
order to overcome this, many POCT devices have systems to run in-built electronic assessments to check 
the electronic performance of the instrument. This is done prior to sample analysis. The QC samples are 
also still run at pre-determined time periods. (Luppa et al, 2016) 
1.3.9 Popular POCT creatinine devices 
Due to the progress made with regard to POCT and development of new devices, there are many devices 
now available. Shephard (2011) produced a mini-review in which the most popular Creatinine POCT 
devices were discussed. Table 1.3 lists devices that are available globally and table 1.4 lists several 
popular POCT creatinine devices along with their respective specifications. 
Table 1.3: Several popular POCT Creatinine devices and their respective specifications (Shephard, 2011). 
Device Statsensor i-STAT ABL 800 
Flex 
Reflotron Dri-Chem 
400 
Piccolo 
Manufacturer Nova 
Biomedical 
Abbott 
POC 
Radiometer Roche Fuji-Film Abaxis 
Method 
principle 
Enzymatic 
with amp 
biosensor 
Enzymatic 
with amp 
biosensor 
Enzymatic 
with amp 
biosensor 
Enzymatic 
with dye 
refelctance 
Enzymatic 
with dye 
absorbance 
Enzymatic 
with 
indicator 
absorbance 
Consumable Dry strip Cartridge Sensor 
cassette 
Dry strip Dry slide Rotor 
Sample type Whole 
blood 
A/C/V 
Whole 
blood A/C 
Whole 
blood 
A/C/V 
Whole 
blood V/C 
Serum or 
plasma 
Whole 
blood, 
serum, or 
plasma 
Sample 
volume (µl) 
1 65 125 C 
250 Syr 
30 10 9 
Analysis time 
(min) 
0.5 2 1 2 5 8.5 
Measuring 
range (µM) 
27-1056 18-1768 10-2000 45-884 18-2122 18-1768 
eGFR 
Calculation 
Yes No Yes Yes No No 
A= arterial  C= capillary  V= venous  Syr= syringe 
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The ideal POCT creatinine meter will require only capillary sampling, fast turn-around-time of results and 
automatic eGFR calculation. In addition it should also have good analytical performance specifications in 
order to correctly categorise CKD risk and/or stages. (Adapted from Shephard, 2011)  
 
1.4 PROJECT OVERVIEW 
1.4.1 Rationale for the study 
This study aimed to bridge the gap in knowledge with regard to the cut-off values for creatinine level 
measurements, and eGFR values, when screening a mixed ancestry populations. Currently, there is only 
documented and standardized cut-offs available for Caucasian and African American populations. 
 This study focused on the African mixed ancestry population and acted as a starting point for 
standardizing POCT creatinine cut-offs for other international mixed ancestry populations. Through the 
standardization of cut-offs for mixed ancestry populations, more accurate screening results can be 
obtained for patients suffering from diseases, which can lead to them receiving early treatment due to their 
early diagnosis. This in turn will help alleviate some of the disease and financial burden on developing 
countries’ health systems because disease progression will be slowed and expensive aggressive 
treatments avoided.  
1.4.2 Objectives of the study 
This study was a comparative study that was designed to evaluate the Nova Statsensor® point of care 
instrument for the measurement of creatinine for the detection of CKD in adult mixed ancestry subjects 
from the Bellville South Community in South Africa. Secondary objectives included (1) the prevalence of 
CKD based on the results of the instrument, and (2) the correlation between the Nova Statsensor®, and 
the central laboratory creatinine values (IDMS traceable). Ancillary objectives of the study were to evaluate 
the technical quality of POCT for creatinine in a community setting, as well as the evaluation of the cost 
implications when introducing this form of POCT into a primary care setting. 
1.4.3 Research Question 
Can a POCT device such as the Nova Statsesnsor® correctly identify subjects with CKD when compared 
with a laboratory method that is IDMS traceable? What is the clinical and diagnostic accuracy of the Nova 
Statsensor® when screening the Bellville South mixed ancestry population.  What are the possible cost 
implications of implementing such a device in local clinics? 
1.4.4 Hypothesis 
The South African mixed ancestry population has a high prevalence of CKD due to studies showing a high 
prevalence of CKD risk factors such as diabetes mellitus, obesity, and hypertension. Implementation of a 
POCT device will allow for increased number of patients screened for CKD thus allowing for early detection 
and intervention in CKD treatment, and can also be used to monitor the disease progression.   
The Nova Statsensor® displays satisfactory accuracy when compared to the IDMS traceable reference 
method. It shows good specificity for eliminating patients with eGFR values above 60 mL/min/1.73m², thus 
making them a non-risk patient for CKD. This means that the POCT will perform adequately in detecting 
true negative results thus eliminating patients without CKD and prevent further expensive laboratory 
testing.  
Implementation of a POCT device will allow for increased number of patients screened for CKD thus 
leading early detection and intervention in CKD treatment, end-stage renal failure, and renal replacement 
therapy. There will be high costs involved in implementation of such a device. 
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2.1 INTRODUCTION 
The study was a comparative study that was designed and aimed to evaluate the performance of the Nova 
Statsensor® point of care instrument, through the measurement of creatinine, for the detection of CKD in 
adult mixed ancestry subjects from the Bellville South Community in South Africa. Secondary objectives 
included (1) the prevalence of CKD based on the results of the POCT instrument, and (2) the correlation 
between the Nova Statsensor®, and the central laboratory creatinine values (IDMS traceable). Ancillary 
objectives to the study evaluating the technical quality of POCT for creatinine in a community setting, as 
well as evaluating the cost implications involved when introducing POCT, for creatinine, into a primary 
care setting. 
 2.1.1 Selection of Nova Statsensor® 
The Nova Statsensor® was previously evaluated in the local laboratory in the division of Chemical 
Pathology, Tygerberg hospital.  
The primary aim was to compare POCT creatinine measurements produced by the POCT Nova 
Statsensor® Creatinine Meter with a laboratory based creatinine measurement performed with the 
Siemens ADVIA® 1800, which used an IDMS standardised kinetic Jaffe assay method. 
The Nova Statsensor® Creatinine Meter was manufactured by Nova Biomedical and makes use 
of amperometric enzymatic biosensor technology. 
This study study made use of the MDRD equation as it measures eGFR directly as opposed to the 
CG-equation which first calculates CrCl. In addition to this, the MDRD equation is able to be 
adjusted for race therefore making it a better candidate as a starting point for developing 
standardized cut offs for ethnic groups other than Caucasians and African Americans.                                     
 
A secondary aim was to assess the performance of the creatinine meter in a clinical setting and to 
assess its diagnostic utility when comparing the eGFR (4-variable MDRD) rate and renal disease 
staging. 
This study involved a group of 45 healthy volunteer patients, attending the Nephrology outpatient 
clinic (Tygerberg Hospital). In this case, “healthy volunteer” refers to their overall health status 
excluding their kidney function. The finger prick method was used to obtain capillary blood sample 
for creatinine measurement on the Nova Statsensor® Creatinine POCT Meter. These results were 
compared to laboratory based serum creatinine method, performed on the Siemens ADVIA® 1800, 
which measured creatinine in venous blood samples. Both capillary and venous blood samples 
were collected at the same time.  
The diagnostic accuracy was determined by comparing the calculated eGFR and different stages 
of renal disease, based on the KDIGO guidelines. 
2.2 METHODS AND MATERIALS 
 2.2.1 Setting 
The study formed part of the Bellville South, South Africa, Study (Matsha et al, 2013), which was 
investigating the prevalence of the independent risk factors for cardiovascular disease in the mixed 
ancestry population of Bellville South in the Western Cape.  
According to 2011 census data (City of Cape Town Metropolitan Municipality 199 from Census 
2011: https://census2011.adrianfrith.com/place/199), the Bellville South Community is a stable 
lower to middle income group of approximately 22000 people, which makes up 76 % of the total 
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population. Approximately 33 % (7200) of the mixed ancestry population is between the age of 35 
and 65. 
2.2.2 Sampling and sample size 
Recruitment of participants from the mixed ancestry population in Bellville South, Ward 9, resulted 
in a stratified random sampling which included participants between the ages of 35 and 65.  
Sample size determination for this study was done using the Australian National Statistical Service 
sample size calculator. A sample size of 845 participants, out of a total at-risk population of 
approximately 7200, was calculated. This conforms to a confidence level of 95% with a 3% 
confidence interval, and an estimated prevalence of the disease of approximately 26% in the 
population with a 90% response rate from the anticipated participants. These rates have been 
obtained from the USA KEEP surveys, in which CKD prevalence rates were estimated using a 
POCT instrument for creatinine measurement. Due to several logistical interferences, only 103 
viable samples were obtained. 
2.2.3 Sample Transport and Separation 
Samples were collected and stored on ice while being transported by motor vehicle to the satellite 
Pathcare™ laboratory at Louis Leipoldt Hospital in Bellville, Cape Town. Once at the Pathcare™ 
laboratory, the blood samples were spun down through centrifugation in order to separate the 
blood serum from the cells. Once separated, the serum samples were then transported, by motor 
vehicle, at room temperature, to N1 City Pathcare™ research laboratory. The urine samples were 
transported in the same manner and to the same location, however these samples were stored on 
ice and not analysed until reaching the N1 City Pathcare™ research laboratory. Once samples 
had reached the Pathcare™ research laboratory creatinine analysis and urine albumin analysis 
were conducted on the relevant instruments. 
2.2.4 Sample Analysis 
The samples (venous) collected for this study were analysed in the Pathcare™ research 
laboratory, which is an accredited laboratory. 
Venous blood samples’ serums were analysed for creatinine measurement using a standardised 
creatinine assay traceable to IDMS performed on the Beckman Coulter AU5800 analyzer, at the 
N1 City Pathcare™ research laboratory. 
The Beckman Coulter AU5800 measures creatinine using a kinetic modification of the Jaffe 
procedure. This involves the creatinine reacting with picric acid, at an alkaline pH, to form a yellow-
orange complex. (Beckman Coulter AU5800 creatinine product insert) 
Urine spot samples were analysed for albumin measurement using the Beckman Coulter, Inc, 
Immage 800 analyzer. Analysis was carried out at the N1 City Pathcare™ research laboratory. 
The Beckman Coulter Immage 800 analyzer involves an antigen-antibody reaction with two forms 
of measurements: the Rate Nephlometry and Rate Turbidimetry systems. 
The chemical reaction is as follows:             
 
 
 
Immunoglobulin (sample) + Particle bound anti-immunoglobulin (antibody)               Immunoglobulin (sample) – Antibody (complex) 
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The Rate Nephlometry system measures the increase in the intensity of light that is scattered by 
particles present in the sample that is in a cuvette. The light source is a 670 nm laser. There is a 
detector that is placed at a 90° angle from the laser beam, in order to measure the light scatter. . 
The Rate Turbidimetry system measures the decrease in the intensity of light that is scattered by 
the particles within the sample that is in the cuvette. The light source for this method is a light 
emitting diode with a wavelength of 940 nm. Detection occurs at 0° from the incident beam. 
(Beckman Coulter Immage microalbumin product insert) 
2.2.5 Measurements 
Capillary blood finger prick samples, from fasting participants, were obtained by the trained 
personnel (Ms Tammy Krige), and measured on the Nova Statsensor® according to the 
manufacturer’s guidelines. The results were documented on the “Patient Result Log” sheets.  
Venous blood specimens were taken by the clinical staff for creatinine measurement by the central 
laboratory. The central laboratory used a method that is traceable to the IDMS gold standard 
reference method.   
In conjunction to the capillary and venous blood samples, a urine sample was obtained from each 
participant in order to measure albumin levels by the conventional laboratory, which made use of 
the Beckman Coulter AU5800. The Beckman Coulter AU5800 used a kinetic modified Jaffe 
method. 
2.2.6 Training 
All personnel carrying out any sample collection were trained in the specific field of sampling 
method, such as venous and capillary blood sampling. All personnel handling the POCT device 
were also trained for the regular maintenance and quality control procedures of the device.  
Protocols for standard point of care operations at the study site were established prior to project 
commencement. 
2.2.7 Quality Control 
Quality control (QC) was conducted according to the manufacturer’s guidelines. For the purposes 
of the study, controls were run on each day that the instrument was used. 
2.2.8 Clinical and Laboratory Measurements 
 All consenting participants received a standardised interview and physical examination during 
which their blood pressure were measured according to the World Health Organisation (WHO) 
guidelines (Chalmers et al. 1999). This was done using a semi-automatic digital blood pressure 
monitor (Rossmax PA, USA) on the right arm, while the participant remained in a sitting position.  
Other clinical measurements included the participant’s body weight, height, waist and hip 
circumferences. Weight (to the nearest 0.1 kg) was determined while the subject was wearing light 
clothing and without shoes and socks.  
An Omron Karada Scan Body Monitor scale was used to measure weight and body mass index. 
The scale was calibrated and standardized using a weight of known mass. 
Height was measured using a Seca stadiometer. Waist circumference was measured using a non-
elastic tape at the level of the narrowest part of the torso, as seen from the anterior view.  
All anthropometric measurements were performed three times and the averaged value was used 
for analysis.  
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Fasting venous samples for various biochemical parameters (as part of the Bellville South, South 
Africa, Study) were obtained through the use of the OGTT.  Morning spot urine samples were 
obtained for microalbumin measurements. 
2.2.9 Laboratory Measurements 
Fasting blood samples were analysed for creatinine. These samples were measured using the 
standardised creatinine enzymatic assay traceable to IDMS performed on the Cobas 6000, 
manufactured by Roche.  
Urine samples were analysed for albumin:creatinine ratio using the immunoturbidimetric assay 
performed on the Cobas 6000. 
2.2.10 Statistical analysis 
Data was captured on the Microsoft Excel 2007 programme where further statistical analysis for 
method comparison, involving linear regression and Bland-Altman plots, was performed using the 
Analyse-It® statistical software version 2.3.  
Diagnostic accuracy, which involved sensitivity, specificity positive predictive value (PPV) and 
negative predictive values (NPV), were calculated to assess the clinical utility of the Nova 
Statsensor® Creatinine POCT Meter. KDIGO Kidney disease stages ≥3 was used as the cut-off 
for CKD. This equates to an eGFR of <60 mL/min/1.73m² for an individual to be classified as having 
CKD. 
 2.2.11 Ethics 
The study was conducted according to the Declaration of Helsinki, and the South African 
Department of Health’s 2004 Guidelines: Ethics in Health Research: Principles, Structures, and 
Processes. Specific oral and written consent by the participants was obtained. Participant 
information and informed consent forms were provided and completed by all participants. The 
forms included all relevant information regarding the current Bellville South, South Africa, Study 
research project. Ethics approval can be found in Appendix A. 
 
2.3 SPECIFICATIONS OF THE NOVA STATSENSOR POINT OF CARE INSTRUMENT FOR 
CREATININE AND EGFR MEASUREMENTS  
2.3.1 Nova Statsensor® Creatinine Meter Specifications 
Acceptable Samples: Whole Blood: Capillary, Arterial, and Venous 
Measurement Range: Creat: 0.30 – 12.0 mg/dL or 27 – 1056 µmol/L 
Test Methodology: Electrochemistry 
Measuring Technology: Enzyme, Amperometric 
Sample Volume: 1.2 µL 
Test Time: 30 seconds 
Meter Memory: 1000 patient tests, 200 QC tests, 4000 Operator profiles 
Battery:  Rechargeable Li-polymer 3.7V 1800 mAh 
Power: 3.7 V Li-polymer battery (Rechargeable/Replaceable)  
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Enzymes 
Enzymes 
+eˉ 
Electrode 
Docking/Charging Station: Desk mount, Input: 100-240 V˜, 50-60 Hz, 0.6A, Output: +12 V, 0.8 A 
Data Output Port: RJ-45 Ethernet (10 Mbit) 
Connectivity: Protocol TCP/IP Ethernet, Standard POCT1-A Compliant 
Electrical Compliance: Meets IEC 61010, UL, and CSA standards 
Dimensions: 153 mm x 82.5 mm x 46 mm 
Weight: 360 g 
2.3.2 Environmental Specifications 
Temperature Range: 15 ⁰C – 40 ⁰C 
Altitude: 4500 meters 
Relative Humidity: Up to 90 % (noncondensing) 
2.3.3 Chemistry Measurement Specifications 
Sealed Test Strip and QC Stability: 12 months (4-8 ⁰C) 
Test Strips: 25 strips per vial 
QC: three levels (low, normal, high) 
 
Table 2.1: Quality control reagents’ level and concentration. 
Control Level Creatinine Levels 
(µmol/L) 
CV % 
Low 88 8 
Medium 440 6 
High 880 4 
 
2.3.4 Creatinine Measurement Methodology 
The creatinine measurement is based on the following methodology: 
Creatinine + O2                                H2O2         (2.1) 
 H2O2 + Ferrocyanide                            Ferricyanide + H2O     (2.2) 
Ferricyanide                           Ferrocyanide       (2.3) 
 
The current generated at the electrode is proportional to the creatinine concentration of the sample. 
(Nova Biomedical user manual, 2012) 
i) eGFR Determination  
The below equation (2.4) will be used by the POCT device to calculate eGFR values of participants. 
This calculation involves the measurement of creatinine levels in participants. This will be done 
using the 4-Variable Modification of Diet in Renal Disease (MDRD-4) equation [Levey et al., 1999; 
2006] which is applicable to standardised serum creatinine values without ethnicity adjustment for 
all participants. Staging of kidney function will be based on the National Kidney Foundation’s 
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Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) classification (Levey et al. 2003). An 
eGFR < 60 mL/min will be used to define chronic kidney disease (or CKD stage 3-5) as previously 
seen in table 1.1. 
The Statsensor® Creatinine Hospital Meter is plasma calibrated and can use several creatinine 
estimation equations: MDRD, IDMS traceable MDRD, Schwartz, Counahan-Barratt and Cockroft-
Gault. (Nova Biomedical user manual, 2012) 
For this study, the modified MDRD-SI equation, which uses the SI creatinine Units µmol/L will be 
used. The MDRD-SI equation is as follows: 
GFR MDRD (mL/min/1.73m²) = 186 x [SCr/88.4]−1.154 x [age]−0.203 x [0.742 if female] x [1.210 if African American] (2.4)
        
The above equation requires 4 variables: 
i. Serum, or plasma, creatinine (SCr) in µmol/L 
ii. Age in years (18 years to 130 years) 
iii. Sex (Male or Female) 
iv. Race (African American or “All other races”) 
 
2.4 VALIDATION OF THE NOVA STATSENSOR CREATININE HOSPITAL METER 
The manufacturers of the Nova Statsensor® Creatinine Hospital Meter have performed an in-house 
method validation, where the instrument displayed satisfactory performance. This information is available 
in Appendix B. 
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CHAPTER 3 
Results and Discussion 
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3.1 RESULTS  
3.1.1 Prevalence of CKD and CKD status 
Table 3.1: Summary of subjects and relevant information. 
Sample 
ID 
Age 
(Years) Gender 
Diagnosis 
(SEMSDA) 
POC 
Creatinine 
(umol/L) 
Lab test: 
CREATININE-
S* (umol/L) 
POC eGFR 
(mL/min/1.73 
m2) 
Lab test: 
MDRD 
(GFR 
ESTIMATE) 
(ml/min) 
Stage 
CKD 
Lab 
Stage 
CKD 
StaSensor 
(KDIGO) 
WC9-
A1860 52 F 
Known 
DM 42 52 >90 > 90 1 1 
WC9-
A1861 38 M Normal 106 71 72 > 90 1 2 
WC9-
A1862 59 M Normal 71 93 >90 72 2 1 
WC9-
A1863 48 M Normal 42 58 >90 > 90 1 1 
WC9-
A1864 73 F IGT 64 59 84 86 2 2 
WC9-
A1865 42 F Normal 43 53 >90 > 90 1 1 
WC9-
A1866 46 F Normal 42 52 >90 > 90 1 1 
WC9-
A1867 74 F IGT 55 64 >90 79 2 1 
WC9-
A1868 67 F Normal 65 50 84 > 90 1 2 
WC9-
A1869 60 F IGT 53 56 >90 > 90 1 1 
WC9-
A1870 68 F Normal 61 69 90 83 2 1 
WC9-
A1871 73 M Normal 72 90 >90 71 2 1 
WC9-
A1872 54 M Normal 58 57 >90 > 90 1 1 
WC9-
A1873 39 M Normal 80 77 >90 > 90 1 1 
WC9-
A1874 22 M Normal 48 61 >90 > 90 1 1 
WC9-
A1875 52 F Normal 57 62 >90 88 2 1 
WC9-
A1876 58 F Normal 35 41 >90 > 90 1 1 
WC9-
A1877 29 F Normal 58 43 >90 > 90 1 1 
WC9-
A1878 45 F Normal 43 46 >90 > 90 1 1 
WC9-
A1879 67 F IGT 45 58 >90 > 90 1 1 
WC9-
A1880 65 F Normal 51 63 >90 82 2 1 
WC9-
A1881 38 F Normal 63 51 >90 > 90 1 1 
WC9-
A1882 42 F Normal 54 56 >90 > 90 1 1 
WC9-
A1883 46 F IGT 70 69 83 80 2 2 
WC9-
A1884 58 F Normal 59 65 >90 81 2 1 
WC9-
A1885 30 F Normal 50 57 >90 > 90 1 1 
WC9-
A1886 80 F Normal 57 66 >90 75 2 1 
WC9-
A1887 43 F Normal 61 60 >90 > 90 1 1 
WC9-
A1888 60 F Normal 46 54 >90 > 90 1 1 
WC9-
A1891 71 F IGT 72 55 74 > 90 2 2 
WC9-
A1892 61 F  IGT/IFG 58 60 >90 88 1 2 
WC9-
A1893 63 F Normal 70 58 78 > 90 2 1 
WC9-
A1894 54 M Normal 59 70 >90 > 90 1 2 
WC9-
A1895 27 M Normal 50 61 >90 > 90 1 1 
WC9-
A1896 74 M IGT 263 275 22 19 1 1 
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WC9-
A1898 60 F 
Known 
DM 60 57 >90 > 90 4 4 
WC9-
A1900 56 M IGT 94 90 77 69 1 1 
WC9-
A1901 68 F IGT 57 65 >90 79 2 2 
WC9-
A1902 58 M IGT 49 47 >90 > 90 2 2 
WC9-
A1903 49 M Normal 67 69 >90 > 90 2 1 
WC9-
A1904 86 M IGT 79 91 86 68 1 1 
WC9-
A1905 44 F DM 65 68 >90 81 1 1 
WC9-
A1906 59 M Normal 57 65 >90 > 90 2 2 
WC9-
A1907 57 M Normal 64 68 >90 > 90 2 1 
WC9-
A1908 57 M Normal 140 129 48 49 1 1 
WC9-
A1909 55 F Normal 49 64 >90 83 1 1 
WC9-
A1910 46 F IGT 39 60 >90 > 90 3a 3a 
WC9-
A1911 51 F 
Known 
DM 59 69 >90 78 2 1 
WC9-
A1912 54 F Normal 42 50 >90 > 90 1 1 
WC9-
A1913 36 F Normal 44 57 >90 > 90 2 1 
WC9-
A1914 39 F Normal 55 63 >90 > 90 1 1 
WC9-
A1915 47 F 
Known 
DM 49 55 >90 > 90 1 1 
WC9-
A1916 59 F 
Known 
DM 76 100 >90 66 1 1 
WC9-
A1917 59 F Normal 44 58 >90 > 90 1 1 
WC9-
A1918 59 F Normal 62 56 >90 > 90 2 1 
WC9-
A1919 55 F Normal 34 46 >90 > 90 1 1 
WC9-
A1920 58 F Normal 56 61 >90 88 1 1 
WC9-
A1921 54 F Normal 50 54 >90 > 90 1 1 
WC9-
A1922 58 F Normal 47 47 >90 > 90 2 1 
WC9-
A1923 27 F Normal 50 46 >90 > 90 1 1 
WC9-
A1925 57 F Normal 58 62 >90 87 1 1 
WC9-
A1926 52 M IGT 79 82 >90 84 1 1 
WC9-
A1928 58 M Normal 65 68 >90 > 90 2 1 
WC9-
A1929 56 M Normal 72 58 >90 > 90 2 1 
WC9-
A1935 55 F 
Known 
DM 59 44 >90 > 90 1 1 
WC9-
A1936 64 F 
Known 
DM 47 48 >90 > 90 1 1 
WC9-
A1937 20 F Normal 54 43 >90 > 90 1 1 
WC9-
A1938 30 M Normal 72 67 >90 > 90 1 1 
WC9-
A1939 49 F IGT 75 53 76 > 90 1 1 
WC9-
A1940 23 M Normal 60 47 >90 > 90 1 1 
WC9-
A1941 42 M Normal 61 65 >90 > 90 1 1 
WC9-
A1942 39 F Normal 50 50 >90 > 90 1 2 
WC9-
A1943 45 M Normal 48 50 >90 > 90 1 1 
WC9-
A1944 53 F Normal 60 59 >90 > 90 1 1 
WC9-
A1945 55 M 
Known 
DM 72 104 >90  1 1 
WC9-
A1946 60 F Normal 64 65 87 81 1 1 
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WC9-
A1947 61 M IGT 79 98 >90 67 1 1 
WC9-
A1949 34 F Normal 66 69 >90 85 2 2 
WC9-
A1950 32 F Normal 50 50 >90 > 90 2 1 
WC9-
A1951 45 F Normal 46 47 >90 > 90 2 2 
WC9-
A1952 47 M Normal 48 72 >90 > 90 2 1 
WC9-
A1953 57 F Normal 42 60 >90 90 1 1 
WC9-
A1954 61 M Normal 54 88 >90 76 1 1 
WC9-
A1955 23 F Normal 37 48 >90 > 90 1 1 
WC9-
A1956 34 F Normal 43 53 >90 > 90 1 1 
WC9-
A1957 24 F Normal 47 47 >90 > 90 2 1 
WC9-
A1961 64 F 
Known 
DM 42 61 >90 86 1 1 
WC9-
A1962 65 M 
Known 
DM 40 81 >90 83 1 1 
WC9-
A1963 44 F 
Known 
DM 45 63 >90 88 1 1 
WC9-
A1964 57 F Normal 40 60 >90 90 2 1 
WC9-
A1965 38 F Normal 46 60 >90 > 90 2 1 
WC9-
A1966 66 F DM 49 72 >90 70 2 1 
WC9-
A1967 52 F Normal 49 68 >90 79 1 1 
WC9-
A1968 65 M DM 46 78 >90 86 1 1 
WC9-
A1969 60 F Normal 54 70 >90 75 2 1 
WC9-
A1970 61 F Normal 58 70 >90 74 2 1 
WC9-
A1971 64 F DM 31 57 >90 > 90 2 1 
WC9-
A1972 68 F Normal 41 88 >90 56 2 1 
WC9-
A1973 53 F Normal 50 53 >90 > 90 2 1 
WC9-
A1974 54 M Normal 53 84 >90 82 1 1 
WC9-
A1975 42 M Normal 54 68 >90 > 90 3a 1 
WC9-
A1980 55 M Normal 50 66 >90 > 90 1 1 
DM = Diabetes mellitus      IGT= Impaired glucose tolerance     IFG= Impaired fasting glusose 
 
Table 3.2: Percentage male and female participants and prevalence of diabetes mellitus, impaired 
glucose tolerance, and impaired fasting glucose within the study group (n=103). 
Gender Number of participants Prevalence (%) 
Female 71 68.93 
Male 32 31.07 
Total 103 100 
Health status 
Normal health 73 70.87 
Known Diabetes mellitus 10 9.71 
Diagnosed Diabetes mellitus 4 3.88 
IGT 15 14.56 
IGT and IFG 1 0.97 
 Total 103 100 
IGT = impaired glucose tolerance   IFG= impaired fasting glucose 
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Table 3.3: Agreement of CKD status between the POCT device and laboratory reference method for the 
three participants, from the study group n=103, who tested positive for stage 3a to stage 5 CKD. 
 
Participant 
(n=3) 
 
Age 
 
Gender 
 
Health 
 
POCT Nova Statsensor® Laboratory reference method 
Creatinine 
(µmol/L) 
eGFR 
(mL/min
/1.73m²) 
CKD 
stage 
Creatinine 
(µmol/L) 
eGFR 
(mL/min
/1.73m²) 
CKD 
stage 
WC9-A1898 60 female DM 54 >90 3a 68 >90 1 
WC9-A1910 46 female IGT 39 >90 3a 60 >90 3a 
WC9-A1975 42 male Normal 60 >90 4 57 >90 4 
Overall prevalence of CKD = 2.91% 
 
Table 3.4: Overall agreement of results between the POCT device and the laboratory reference method, 
displayed as a percentage of the number of aligned results out of the total of 103 participants’ results. 
 POCT aligned 
with laboratory  
reference method 
(% that aligned) 
POCT non-
alignment with 
laboratory  
reference method 
(% that did not 
aligned) 
Over-estimation of 
value 
(%) 
Under-estimation 
of value 
(%) 
Creatinine values 2.88 96.12 34.95 61.17 
eGFR values 55.34 44.66 37 of 103 8.74 
CKD staging 66.99 33.01 29 of 103 4.85 
 
Table 3.4 deals with the overall agreement of results between the POCT Statsensor® results and the 
laboratory method.  
3.1.2 Laboratory evaluation  
Imprecision (coefficient of variance, CV %) on the POCT device was evaluated using repeated analysis 
of two levels of Nova Statsensor® quality control (QC) material. The accuracy of creatinine results 
obtained with Nova Statsensor® device was compared to the results obtained with the laboratory 
reference analyzer (Siemens ADVIA® 1800) using spiked (different creatinine concentrations) donor 
heparinised venous blood samples. This analysis was carried out by Dr Megan Rensburg. 
 
Table 3.5: Imprecision evaluation of the POCT Nova Statsensor® compared to the laboratory reference 
analyser (Siemens ADVIA® 1800) .  
 Control level 1 
(n=20) 
44-124 µmol/l 
Control level 2 
(n=20) 
398-663 µmol/l 
Within-day CV% 5.3 0.8 
Between-day CV% 4.4 2.4 
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y =     1.2x + 14.8    R2 = 0.98 
Figure 3.1: POCT device accuracy versus the laboratory reference method. 
3.1.3 Clinical setting 
3.1.3.1 Renal Clinic Patients 
 
 
Figure 3.2: Linear regression curve between the Nova Statsensor® and reference method, ADVIA® 1800.  
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Figure 3.3: Bland-Altman plot depicting total allowable error (Westgard guidelines, 
https://www.westgard.com/biodatabase1.htm)  
 
Table 3.6 Diagnostic accuracy results of the clinical setting evaluation. 
≥ Stage 3 CKD % 
Sensitivity 66.67 
Specificity 100 
PPV 100 
NPV 99 
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3.1.4  Bellville South community participants results 
 
Figure 3.4: Scatter plot depicting the correlation between the Nova Statsensor® POCT device and the 
laboratory reference method (Bellville-South Project). 
According to figure 3.4, there is negative proportional bias for the Nova Statsensor®.  
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3.1.4.1 Method comparison 
 
Figure 3.5: Bland-Altman difference plot depicting total allowable error. 
Figure 3.5 demonstrates that there is a total allowable error (TEa) of 8.9%, based on the Westgard 
Guidelines, with creatinine biological variation within-subjects being 14.7 and between-subjects 2.98. In 
this Bland-Altman graph, which measures the agreement between the two methods, one can see that the 
larger the mean creatinine value, the larger the range of total allowable error. In this graph it appears that 
more than half the values fall outside of the TEa range.  
3.1.5 Diagnostic accuracy 
Table 3.7: Diagnostic accuracy calculated using eGFR values and subsequent staging of CKD, with the 
laboratory method as the reference method. 
≥ Stage 3 CKD % 
Sensitivity 66.67 
Specificity 100 
PPV 100 
NPV 99 
 
Table 3.7 displays excellent diagnostic accuracy when looking at eGFR values and CKD staging.  
3.1.6 Cost implications of introducing the Nova Statsensor® into primary care 
Introducing such a device into a primary care setting within a community will initially be extremely 
expensive. It will involve buying stock consisting of test strips, control solutions, and also involve buying 
the device itself. Based on this study, the expenses involved in introducing this method of testing are 
presented in the below table 3.8. This data was generated by Ms Tammy Krige. 
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On average the NHLS laboratory at Tygerberg Hospital receives 22 444 number of requests for patient 
Creatinine testing monthly. One must consider adding additional tests in order to cover QC testing and 
patient re-testing. Based on the information provided by the NHLS laboratory at Tygerberg Hospital, this 
brings the total approximate number of monthly creatinine tests conducted to 22 970.  
Table 3.8: Monthly expenses for Statsensor® Creatinine Meter consumables based on running 22 970 
tests per month. 
Product Cost per unit (R) Number of units 
required to cover 
22970 creatinine 
tests per month 
Cost for 1 month 
supply based on 
22970 tests run per 
month (R) 
Nova Biomedical 
Statsensor® Creatinine 
Test Strips (50’s) 
5 796.90 460 2 666 574 
Control Solution Level 1 
(4mL bottle) 
191.84 1 191.84 
Control Solution Level 3 
(4mL bottle) 
191.84 1 191.84 
Total 960.58 - 2 666 957.68 
 
Purchasing the Statsensor® Creatinine Meter KIT will be an initial once off expense, the total amount is 
included in table 3.9 as the first month’s total expenses for implementation. 
 
Table 3.9: Total costs involved in the first month of POCT implementation when the Statsensor® 
Creatinine Meter KIT is paid as a lump sum. 
Product Total cost (R) 
Statsensor® Creatinine Connectivity Data 
Management Meter KIT (including Docking 
Station, power adapter, and rechargeable battery) 
104 344.20 
Month supply of consumables (as seen in table 
3.8) 
2 666 957.68 
Total 2 771 301.88 
 
If, for example, a 24 month payment plan is in place, it will cost the State a relatively constant amount for 
each month. This amount will include the Statsensor® Creatinine Meter KIT fee and a month’s supply of 
consumable stock, as seen in the below table 3.10, which may vary slightly for the odd month based on 
increased or decreased test demands. 
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Table 3.10: Monthly expenses involved in purchasing the Statsensor® Creatinine Connectivity Data 
Management Meter KIT with a 24 month payment plan. 
Product Cost per unit Cost for 1 month supply 
based on 22970 tests run per 
month with payment plan of 
24 months(R) 
Nova Biomedical Statsensor® 
Creatinine Test Strips (50’s) 
5 796.90 2 666 574 
Control Solution Level 1 (4mL 
bottle) 
191.84 191.84 
Control Solution Level 3 (4mL 
bottle) 
191.84 191.84 
Statsensor® Creatinine 
Connectivity Data Management 
Meter KIT (including Docking 
Station, power adapter, and 
rechargeable battery) 
104 344.20 4347.68 
Total 2 771 301.88 2 666 957.68 
 
Making use of a payment plan is especially feasible for developing countries when implementing POCT 
because it lessens the initial financial load on the health care system as a monthly budget can be set up 
in order to ensure even distribution of medical funds for throughout the year. 
 
3.2 Discussion 
The study investigated the prevalence of CKD based on the results of the Nova Statsensor® POCT instrument. 
The study also evaluated the correlation between the Nova Statsensor®, and the central laboratory creatinine 
values (IDMS traceable). Additionally, the technical quality of Nova Statsensor® POCT device, testing for 
creatinine, was assessed within a community setting. The study also evaluated the cost implications involved 
in implementing the POCT into a community care setting. The study results provide a CKD prevalence of 2.9% 
with the mixed ancestry study population. The study found that the creatinine value correlation between the 
POCT device method and the laboratory reference method, was very poor with only 3.89% of the POCT 
values correlating to the reference method results. The eGFR values had better agreement with 55.34% 
correlation between the POCT device measurement and the central laboratory measurement. The two 
methods correlated well in terms of CKD staging with 67% agreement. The study found a low sensitivity 
of only 66.7% and a high specificity of 100% for the Nova Statsensor® when compared against the 
laboratory reference method. The technical quality of the Statsensor® was satisfactory as it was user 
friendly. The cost of implementation of the Nova Statsensor® POCT device would cost the State R 2 771 
301.88 for device implementation and 1 month supply of relevant consumables. This price would mostly 
be unaffordable for governments, especially those of developing countries. 
The study group of 103 participants consisted mainly of females (68.9%) and the majority (70.9%) of 
participants had a health status of normal health, with no additional health issues. However 9.7% of the 
study group suffered from known, pre-existing DM. Through the study 3.9% were diagnosed with DM and 
it was also found that 14.6% of the participants suffered from IGT. A very small percentage, (0.97%) 
suffered from both IGT and IFG. These are all risk factors for developing CKD. Based on these figures, 
the prevalence of risk factors was 29.1% that is almost a third of the population at risk of developing CKD. 
This is considered a high prevalence within the mixed ancestry population, especially when considering 
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the Nigerian African population diabetes prevalence is 2.1% and 2.8% in the African Cameroonian 
populations. These results were found in studies conducted by Okoye et al (2011) and Kaze et al (2015) 
respectively. 
The total prevalence of CKD within the study group tested by the POCT device was 2.9%, which can be 
statistically translated to: for every 100 mixed ancestry persons, three will suffer from CKD. The 2.9% 
prevalence finding of this study are considerably lower than that of the study conducted by Matsha et al 
(2013), where the prevalence was found to be 7.6% for MDRD equation adjusted for ethnicity and 23.9% 
when not adjusting for ethnicity. The difference in prevalence between the two studies could be due to the 
differences in sample size. Matsha et al (2013) had a final sample size of 1202 with 75.3% of participants 
being female and the average age being 52.9 years of age, compared to this study having only 103 
participants and which had 68.9% females with an average age of 52.2 years of age. These dynamics 
within the sample groups may also partially account for the lower CKD prevalence in this study. Other 
possible influential dynamics may include the mean age of the sample population and difference in 
prevalence of CKD risk factors such as diabetes and hypertension. However in these two studies the 
mean ages were very similar therefore eliminating this dynamic as a possible influence of the difference 
in CKD prevalence. Similarly the prevalence of diabetes within both studies’ populations were 26.4% for 
Matcha et al (2013) and 29.2% for this study. Again, these values are significantly similar therefore 
eliminating diabetes as an influential dynamic on the difference in studies’ prevalence of CKD. The only 
major differing possible influential factors include sample size and gender composition of each study. 
Matsha et al (2013) had a much larger sample size comprising of mainly female participants (75.3%), 
whereas this study had a female population of only 68.93%. A study conducted by Eriksen and Ingebretsen 
(2006) found that females had a higher prevalence of CKD than their male counterparts, this supports the 
finding by Matsha et al (2013) versus this study. In this study there was a population of 68.9% females 
whereas Matsha et al (2013) had a female population of 75.3%. This could have possibly led to the higher 
prevalence of CKD found in the study conducted by Matsha et al (2013).  
The three participants, of the 103 subject population, that the POCT Nova Statsensor® determined to 
have CKD show good agreement between the POCT and laboratory testing methods when based on 
eGFR values. However when the creatinine values are assessed it is noted that Statsensor® under 
estimated the creatinine values in the female participants and overestimated the creatinine levels in the 
male participant, if only by 3 µmol/L. The underestimation is a concern as it can lead to CKD positive 
patients obtaining a false negative result. Based on this table, the Statsensor® and laboratory reference 
method agree on two of the three CKD staging results of the listed participants. It was noted that in 
participant WC9-A1898 the gap between the stages produced by each method was notably large. The 
POCT device diagnosed stage 3a where the laboratory method diagnosed as stage 1. Again it is better 
to have an over estimation as this will lead to less patients receiving false negative results, and instead 
receive a false positive result which will lead to a referral for further testing thus confirming their health 
status. This is a good precautionary measure, unfortunately it may lead to increased unnecessary 
expenses for the government health sector. The total prevalence of CKD within the study group tested 
by the POCT device was 2.9%, which can be statistically translated to; for every 100 mixed ancestry 
persons, three will suffer from CKD. The laboratory method found a prevalence of only 1.94% due to 
participant WC9-A1898 receiving a false positive on the POCT device. This number can easily increase 
over time due to the high prevalence of CKD risk factors within the mixed ancestry population.   
The overall agreement of results between the POCT Statsensor® results and the laboratory method show 
that the creatinine value agreement was very poor with only 3.89% of the POCT values correlating to the 
reference method results. The POCT Statsensor® also mainly under-estimated creatinine results, 61.17% 
underestimated, which is not desirable as this may possibly lead to false negatives. The eGFR values had 
better agreement, 55.34%, however these were mainly over estimated by the Statsensor®. This can again 
lead to false negatives. The two methods agreed well in terms of CKD staging with 67% agreement. 
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However it again over estimated some of the results therefore suggesting an over estimation of 
progression of CKD. This is not a massive concern as the result will most likely be false positives arising 
which will lead to further referrals thus preventing patients going untreated for CKD. Additional analysis 
using the Youden Index method and Receiving Operating Characteristics (ROC) curve can add additional 
insight into the agreement between the two methods, however this analysis was not performed during this 
study.  
The comparability of the POCT device against the reference method could not be measured using 
creatinine values alone as the creatinine levels showed poor correlation between the two methods of 
measurement. Therefore one must rather make use of the MDRD equation for eGFR calculation which 
gives rise to improved correlation. This is because creatinine levels depend on several factors which 
include muscle mass, obesity, gender, and age. In addition, creatinine has a wide reference interval which 
also contributes to it being undesirable as a sole marker for measurement. The MDRD equation factors in 
these variables and thus adjusts the results to make them more relevant and accurate. There are several 
other eGFR equations that include IDMS traceable MDRD, Schwartz, and Cockroft-Gault. 
The Bland-Altman difference plot depicting total allowable error brings to question whether its results, with 
many values falling outside the TEa range, are due to analytical error or simply biological error, which may 
result in altering the final eGFR value from the POCT device. Possible biological interferences include 
several possibilities. The first being antibiotics such as aminoglycosides, particularly Streptomycin which 
has been found to almost double the apparent creatinine concentration, this can be exacerbated by the 
risk of possible nephrotoxic effects on the kidneys which will decrease kidney function and further increase 
the apparent creatinine concentration. Other antibiotics such as cephapirin, cefazolin, and cephalthin have 
also been found to interfere with creatinine measurement at various concentrations (Syal et al. 2013). 
These compounds were not tested for in this study as Nova Biomedical states that there is negligible 
interference on the POCT device with regard to the former mentioned compounds. The second possible 
biological interferences include bilirubin, glucose, and acetone being present within the blood (Syal et al. 
2013). These compounds have been found to affect the Jaffe method. This is important because in this 
study the reference analytical method was based on a Jaffe assay. This leads to the possibility that 
unexpected biological interferences could have occurred. The dispersion could also be due to the 
difference in analytical methods of creatinine measurement. The Nova Statsensor® makes use of 
electrochemistry to measure creatinine using an enzyme and amperometric measuring technology. The 
laboratory method is run on the Beckman Coulter AU5800 and makes use of a kinetic modified Jaffe 
method which is a colorimetric method. According to Nova Biomedical the Nova Statsensor® is IDMS 
traceable, therefore traceability of the POCT device is not an issue (Nova Biomedical Statsensor® 
pamphlet insert). Based on this graph it appears that there is sub-optimal agreement between the two 
methods. 
According to the results there is excellent diagnostic accuracy when looking at eGFR values and CKD 
staging. A 100% specificity was recorded which is a desired result as this study aims to eliminate 
participants who test negative for CKD and have a eGFR value of above 60 ml/min/1.73m², or are staged 
as stage 1 or 2. Screening programs work through elimination of healthy individuals. If an eGFR value is 
below 60 ml/min/1.73m² and staging is stage 3a or beyond, then the patient will be referred for further 
medical tests in order to make a definite diagnosis. Specificity and sensitivity and co-dependent values, 
therefore due to the high specificity, the POCT device has a lower sensitivity of 66.67%. These are 
acceptable results and are supported in a study conducted by Shephard et al (2010) where they found the 
specificity to also be 100% and the sensitivity to be 87%. However it must be taken into account that the 
low sensitivity of 66.67% indicates that the Statsensor® has a low ability to test for true positives, but when 
the high specificity is taken into account it can be concluded that the Statsensor® is more likely to produce 
false positives where patients without CKD are tested as positive. This is an acceptable characteristic as 
it will ensure that patients with existing CKD will not be missed. These results suggest that 33.33% of all 
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tests will test as false positive. In the case of this study, this translates to 34 participants receiving a false 
positive result. The problem with a third of all tests being false positive is that it will result in many referrals 
for further laboratory testing which may incur unnecessary expenses for the State. 
The positive predictive value (PPV) and negative predictive value (NPV) are 100% and 99% respectively. 
Therefore one can 100% certain that a positive result is a true positive result, making it easy to identify 
patients who need further diagnostic testing for CKD status. The NPV value allows one to be 99% certain 
that a negative result on the POCT device is a true negative result, therefore the patient does not require 
further diagnostic testing. Statistically only 1 in 100 screened patients may receive a false negative result 
according to this NPV. These results seem to contradict the results of the 66.67% sensitivity resulting in 
roughly a third of all tests testing as false positives. 
Overall, possible errors leading to the non-alignment of data could be due to pre-analytical errors where 
samples were not kept on ice during transit to laboratory, or possibly due to incorrect sampling procedure 
followed when using the POCT device (Plebani M. 2012). Non-alignment of results between the two 
methods can also be due to interferences in each one of the two methods. Interference of less than 20% 
can occur between 3 and 12g/dL of protein in the Beckman Coulter AU5800 reference method (Beckman 
Coulter Creatinine pamphlet insert), with no known significant interferences in the Statsensor® (Nova 
Biomedical Statsensor® creatinine meter pamphlet insert). This study did not test for interferences.  
The IDMS-traceable MDRD, a modified MDRD equation recalculated with serum creatinine 
measurements that are calibrated to an IDMS traceable enzymatic assay, equation involves the variables 
as found in equation 2.4 and is favourable as it requires minimal patient information. The Cockcroft-Gault 
equation has the limitation that it estimates creatinine clearance without being normalised to 1.73 m² body 
surface area, unlike the MDRM equation. The Cockcroft-Gault equation requires accurate body weight 
which is not always readily available. This equation and the Schwartz equation were both developed using 
an outdated Jaffe assay for creatinine measurement, which reflects true creatinine. The Schwartz equation 
involves a k constant that differs for age groups and gender. The k constant should be determined by the 
institute against gold standard GFR measurements. K constants are also significantly dependant on age 
and are closely associated with muscle mass. This is difficult to assess in individual patients thus making 
it a challenging equation to make use of. (Herget-Rosenthal et al. 2007) 
This study found that the Nova Statsensor® did not measure CKD as accurately as expected when 
compared against the laboratory reference method, with only a 66.7% sensitivity. This is due to the poor 
agreement of the direct creatinine measurement and eGFR values between the Statsensor® and the 
laboratory reference method. These finding are supported Shephard et al (2010) where the Statsensor® 
performance was compared to the Roche enzymatic assay, and performance was found to be lacking. 
However the CKD staging results displayed a specificity and positive predictive values of 100% therefore 
demonstrating excellent diagnostic accuracy. 
The study’s findings of inadequate accuracy are however contradicted in a study conducted by Srihong et 
al (2012) where adequate accuracy was established. This contradiction may be due to the fact that Srihong 
et al conducted their study on in vitro stored sample whereas this study was conducted using blood directly 
sampled from participants in a community setting.  
Schnabl et al (2010) also stated results that contradict the findings of this study, where they found 
acceptable correlation between the POCT device results and laboratory reference method results. A 
possible explanation for these contradicting results could be that Schnabel et al used a larger population 
of 191 renal patients only. 
The technical quality of the Statsensor® was satisfactory as it was user friendly, requiring only 1.2 µl of a 
finger stick blood sample. It also had an incredibly short turn-around-time of 30 seconds. These attributes 
make the Nova Statsensor® a desirable POCT device for community based screening programmes, 
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therefore further standardization to IDMS traceability may prove worth the effort and possibly improve the 
Statsensor® to be used as a diagnostic tool. Having said this, the Nova Statsensor® would be an adequate 
tool as a screening device for CKD within communities. 
The cost of implementation of this POCT device and all the relevant consumables for 1 month will cost 
the State R 2 771 301.88. This price is mostly unaffordable for governments of developing countries and 
thus would most likely require a budget plan to be implemented in order to save up for implementation. 
Other than that, in reality it would be too costly to implement. In addition to the high expenses, there is 
also the requirement for training personnel on the proper use of the device, this is time consuming and 
will possibly require additional funding. 
Strengths of this study include a wide range of ages used and the study included both male and female 
participants. The study also included patients with pre-existing conditions that relate to CKD, therefore 
demonstrating the possible relationship between CKD and several of its risk factors. Another strength of 
this study was that Nova Biomedical stated that the Nova Statsensor® displayed negligible interference 
from the following compounds at their respective concentrations: acetaminophen (66.14 µmol/L), ascorbic 
acid (198.73 mmol/L), bilirubin (256 mmol/L), cholesterol (25.9 mmol/L), creatine (305 mmol/L), glucose 
(27.75 mmol/L), heparin (120 U/dL), triglyceride (11.3 mmol/L), uric acid (1189.7 mmol/L), and 
haemoglobin (up to 1.61 mmol/L). This made it unnecessary to test for additional compound interference 
as it was highly unlikely that non-comparable values were due to interference from other compounds found 
within the blood sample, this being based on the manufacturer’s claims. 
The weakness of the study was that there was a very small sample size used. There was also room for 
pre-analytical errors such as inadequate finger prick sampling, where one forgot to wipe away the first 
drop of blood as directed by the manufacturer, or venous blood sample being inadequately stored during 
transportation. Possible areas of improvement include a larger sample size.  
This study is unique in that it was conducted in a mixed ancestry population in a community setting under 
community clinic conditions, where samples were collected and analysed within 24 hours of collection. 
Whereas the above referenced studies by Schnable et al and Srihone et al were conducted in a laboratory 
setting using stored samples collected from hospital renal patients. 
 
3.3 Conclusion 
Our results demonstrated an overall correlation between Statsensor® and the laboratory reference 
method that was less than initially anticipated, however the study did find a relatively high prevalence of 
CKD within the small sample group, thus reiterating the need for community screening programs. This 
study demonstrates that there is a need to implement infrastructure in order to equip communities with 
means of running screening programmes in order to combat the ever rising prevalence of CKD and its 
relevant risk factors. Currently, developing countries cannot afford such infrastructure which opens a 
window of opportunity for the development of cheaper alternative testing methods that still remain user 
friendly. The study highlights a need for the establishment and standardization of creatinine and eGFR 
cut-offs for the many different mixed ancestry populations globally, as there may well be variation between 
ethnic groups. Our results also demonstrate that eGFR measurement using the MDRD equation is a better 
method of measuring CKD, rather than using creatinine values alone.  
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APPENDIX A – ETHICS CLEARANCE 
 
Approval Notice 
 
Response to Modifications- (New Application) 
 
 
17-Aug-2015 
Erasmus, Rajiv 
RT 
 
Ethics Reference #: N15/05/045 
Screening for Chronic Kidney Disease (CKD) in a high risk population using a 
 
Title: Point Of Care Instrument for creatinine measurement – a community based 
 
Study (The Bellville-South Africa Study). 
 
Dear Prof Rajiv Erasmus, 
 
The Response to Modifications - (New Application) received on 30-Jul-2015, was reviewed by 
members of Health Research Ethics Committee 2 via Expedited review procedures on 30-Jul-2015 
and was approved. 
 
Please note the following information about your approved research protocol: 
 
Protocol Approval Period: 17-Aug-2015 -17-Aug-2016 
 
Please remember to use your protocol number (N15/05/045) on any documents or correspondence 
with the HREC concerning your research protocol. 
 
Please note that the HREC has the prerogative and authority to ask further questions, seek 
additional information, require further modifications, or monitor the conduct of your research and the 
consent process. 
 
After Ethical Review: 
 
Please note a template of the progress report is obtainable on  www.sun.ac.za/rds and should be 
submitted to the Committee before the year has expired. The Committee will then consider the 
continuation of the project for a further year (if necessary). Annually a number of projects may be 
selected randomly for an external audit. 
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Translation of the consent document to the language applicable to the study participants should be 
submitted. 
 
Federal Wide Assurance Number: 00001372 
 
Institutional Review Board (IRB) Number: IRB0005239 
 
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it 
pertains to health research and the United States Code of Federal Regulations Title 45 Part 46. This 
committee abides by the ethical norms and principles for research, established by the Declaration of 
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical 
Research: Principles Structures and Processes 2004 (Department of Health). 
 
Provincial and City of Cape Town Approval 
 
Please note that for research at a primary or secondary healthcare facility permission must still be 
obtained from the relevant authorities (Western Cape Department of Health and/or City Health) to 
conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western 
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at 
City Health (Helene.Visser@capetown.gov.za Tel: +27 21 400 3981). Research that will be conducted 
at any tertiary academic institution requires approval from the relevant hospital manager. Ethics 
approval is required BEFORE approval can be obtained from these health authorities. 
 
We wish you the best as you conduct your research. 
 
For standard HREC forms and documents please visit:  www.sun.ac.za/rds 
 
If you have any questions or need further assistance, please contact the HREC office at 219389207. 
 
Included Documents: 
 
Checklist 
 
CV R Erasmus 
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Protocol 
 
CV A Zemlin Application form Declaration R Erasmus Declaration A Zemlin 
Declaration M Rensburg MOD_Protocol Payment form 
Protocol Synopsis 
 
MOD_Cover letter_Response to modifications CV M Rensburg 
 
Sincerely, 
 
Mertrude Davids 
 
HREC Coordinator 
 
Health Research Ethics Committee 2 
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APPENDIX B – Validation of the NovaStatsensor Creatinine Hospital Meter 
Nova Biomedical provided their in-house validation method for the StatSensor-i Creatinine 
Meter. They made use of 5 predicate devices, that they had previously manufactured and 
validated, for the comparison studies. Below are the details of said predicate devices. 
Table 1: Predicate devices used in the comparison studies of the Nova StatSensor-i 
Craetinine Meter as part of the Nova Biomedical validation study. (Information provided by 
Nova Biomedical, as part of their FDA clearance documentation) 
 
Characteristic Proposed Nova 
StatSensor 
Predicate Beckman 
Synchron LX-20 
Predicate Beckman 
Synchron LXi 7251 
Predicate Bayer 
ADVIA 1650 
Predicate Dade 
Dimension RXL 
Predicate  
i-STAT with 
Creatinine Cartridge 
K Number New k965240 k023049 k990346 k043546 k973292 
Measuring 
Range 
0.3-12.0 mg/dL 0.3-25.0 mg/dL 0.3-25.0 mg/dL 0.2-37.0 mg/dL 0.2-30.0 mg/dL 0.2-20.0 mg/dL 
Operating 
Principle 
Electrochemical biosensor 
test strip 
Random access 
processing analyser 
using a colorimetric, 
kinetic rate reaction 
Random access 
processing analyser 
using a colorimetric, 
kinetic rate reaction 
Automated analyser, 
UV rate reaction 
Discrete chemistry 
analyser measuring 
kinetic rate reaction 
Electrochemical 
biosensor cartridge 
Intended Use The Nova StatSensor-i 
Creatinine Hospital Meter 
System is intended for in 
vitro diagnostic use by 
health care professionals 
for the quantitative 
measurement of creatinine 
in capillary, venous, and 
arterial whole blood. It is 
indicated for the use in a 
clinical setting by 
healthcare professionals 
as an aid to monitor kidney 
function. 
In vitro diagnostic use 
by health care 
professionals for the 
quantitative 
measurement of 
creatinine in serum 
In vitro diagnostic use by 
health care professionals 
for the quantitative 
measurement of 
creatinine in serum 
To measure the 
creatinine levels in 
serum and urine 
In vitro diagnostic 
assay for the 
quantization of 
creatinine in human 
serum  
For the quantitative 
determination of 
creatinine in whole 
blood. 
Sample Type Whole blood Serum  Serum Serum Serum Whole blood 
Sample Size 1.2 µL 20 µL 20 µL 2 µL of a 1:5 diluted 
solution 
3 µL diluted serum 65 µL 
Sample 
Application 
Test strip capillary draw Automatic sample 
aspiration from sample 
cups 
Automatic sample 
aspiration from sample 
cups 
Sample Tray  84 
samples, positive 
sample identification 
Auto-sampling from 
vacationer type 
tubes or sample 
cups 
Test cartridge syringe 
or capillary fill tube 
Handheld 
Meter? 
Yes No No No No Yes 
Meter 
Calibration 
Automatic, no Calibration 
Code 
Automatic, at least 
every 5 days 
Automatic, at least every 
5 days 
Automatic 2-point liquid 
calibration 
Automatic Automatic calibration 
with each cartridge 
Data Storage 1200 Unlimited using 
DL2000 data manager 
Unlimited 70 000 patient samples Unlimited, based on 
available hard disk 
storage space 
5 000 test results 
Test Time 30 seconds 25 seconds 25 seconds 20 seconds 20 seconds 120 seconds 
Weight 8.8 oz 1 620 lb 2 701 lb 1 178 lb 800 lb 18.34 oz 
Bar Code 
Scanner? 
Yes Yes Yes Yes Yes Yes 
Power Source Rechargeable 3.7 V 
Lithium battery 
115 or 220 V outlet 115 or 220 V outlet 100-240 V main  110-130 V outlet 2.9 V batteries 
Accessories: Charging/Data Upload 
Station Base Unit 
Data manager data manager, 
automated sample rack 
system 
Data management 
system 
N/A N/A 
Controls: Liquid, 3 levels 2 levels 2 levels 3 levels 3 levels Liquid, 3 levels 
Linearity 
Solutions 
Liquid, 5 levels 5 levels 5 levels 5 levels 5 levels Liquid, 5 levels 
Test Strip/ 
Cartridge Active 
Reagent: 
Creatinine 
amidohydroliase, creatine 
amindinohydrolase and 
sarcosine oxidase 
Jaffe rate method 
(kinetic alkaline 
picrate) 
Jaffe rate method 
(kinetic alkaline picrate) 
Enzymatic UV 
reaction/alkaline 
picrate reagent 
Alkaline picrate, 
coloimetry, 
creatinine 
Creatinine 
amidohydroliase,  
creatine 
amindinohydrolase 
and sarcosine 
oxidase 
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2.4.1 Analytical Performance  
i) Precision/Reproducibility 
Precision studies were conducted based on Clinical and Laboratory Standards Institute 
(CLSI) EP5-A2 (Evaluation of Precision Performance of Quantitative Measurement 
Methods).  
 Day-to-day precision was evaluated using two meters and two lots of test strips 
on site of the sponsor. Samples were run in duplicate and all 3 levels of controls 
were used. Precision testing was run daily for 20 days.  
 
Table 2: Results outline of day-to-day precision evaluation. 
 
Strip Lot Control 
Level 
Range 
(mg/dL) 
Mean CV% Number 
of 
samples 
Duration 
(days) 
6080301 L1 0.8-1.5 1.06 8.39 80 20 
L2 1.7-2.5 2.09 5.80 80 20 
L3 4.0-7.0 6.14 3.35 80 20 
6080401 L1 0.8-1.5 1.08 8.68 80 20 
L2 1.7-2.5 2.09 5.87 80 20 
L3 4.0-7.0 6.11 3.59 80 20 
 
 Within-run precision was established using protocol based on the CLSI EP5-
A2 and involved two meters and three lots of strips. Three levels of controls 
were tested in replicates of 20. For each lot of strips tested the controls were 
prepared separately. In addition, three blood samples with target creatinine 
concentrations of 0.3-1.5, 2.5-4.5, and 6.0-12.0 mg/dL were prepared.  
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Table 3: Pooled data of within-run precision evaluation 
 
Blood Samples 
Strip Lot Blood 
Level 
(mg/dL) 
Mean 
(mg/dL) 
Ref Value 
(mg/dL) 
CV% Number of 
samples 
6072601 0.3-1.5 0.98 0.9 8.73 20 
2.5-4.5 2.43 2.6 2.95 20 
6.0-12.0 6.95 6.6 4.42 20 
      
6072701 0.3-1.5 1.11 1.0 8.03 20 
2.5-4.5 3.94 4.1 3.52 20 
6.0-12.0 10.64 9.9 5.16 20 
      
6072702 0.3-1.5 0.99 0.9 9.48 20 
2.5-4.5 3.53 3.6 4.77 20 
6.0-12.0 10.23 10.0 5.91 20 
Control Samples 
Strip Lot Control 
Level 
(mg/dL) 
Mean 
(mg/dL) 
SD CV% Number of 
samples 
6072601 L1 (0.8-
1.5) 
1.12 0.06 5.27 20 
L2 (1.7-
2.5) 
2.14 0.05 2.29 20 
L3 (4.0-
7.0) 
6.16 0.30 4.84 20 
      
6072701 L1 (0.8-
1.5) 
1.13 0.08 6.99 20 
L2 (1.7-
2.5) 
3.94 0.14 3.52 20 
L3 (4.0-
7.0) 
6.20 0.36 5.83 20 
      
6072702 L1 (0.8-
1.5) 
1.10 0.06 5.52 20 
L2 (1.7-
2.5) 
2.16 0.05 2.33 20 
L3 (4.0-
7.0) 
6.25 0.31 4.91 20 
 
The above mentioned protocol was followed while conducting the within-run 
precision study at three different Point of Care sites, where the tests were carried 
out by typical Point of Care staff. It was found that there was no significant 
difference in precision at the various sites. 
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Table 4: Summary of within-run precision results at the three different Point of Care 
testing sites. 
 
 Site 1 Site 2 Site 3 
Target Range (mg/dL) Target Range (mg/dL) Target Range (mg/dL) 
0.5-1.5 3.0-5.0 8.0-12.0 0.5-
1.5 
3.0-
5.0 
8.0-
12.0 
0.5-1.5 3.0-5.0 8.0-12.0 
Mean 0.84 4.42 11.42 0.88 4.10 11.38 0.84 4.53 8.15 
SD 0.08 0.34 0.85 0.09 0.17 0.60 0.05 0.13 0.26 
CV% 9.73 7.72 7.43 10.41 4.26 5.24 5.86 2.77 3.25 
 
ii) Linearity/assay reportable range 
The Nova StatSensor-i Creatinine Meter, with a measuring range of 0.3-12.5 mg/dL, 
was assessed for linearity using the protocol based on the CLSI EP6-A (Evaluation of 
Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved 
Guideline Evaluation of Matrix Effects).  
Venous blood samples were prepared by spiking blood with 5 different concentration 
of creatinine and 3 levels of haematocrit. 2 meters were used where 5 replicates were 
run at each level. A total of 30 samples were run at each creatinine concentration.  
 
The results obtained were: 
Y = 1.0068 x – 0.0398        
 (2.5) 
r² = 0.9927          
 (2.6) 
n = 450          
 (2.7) 
These results were said to support the claimed linearity range. 
 
iii) Traceability, Stability, Expected values (controls, calibrators, or methods) 
The Nova StatSensor-i Creatinine controls and linearity solutions values are traceable 
to the NIST SRM967 Creatinine. Criteria for acceptance between the NIST Creatinine 
standard and Nova Control solutions are +/-5% (L1), +/-4% (L2), and +/-3 (L3). The 
expected control range values are as follows: L1=0.8-1.5 mg/dL, L2=1.7-2.5 mg/dL, 
L3=4.0-7.0 mg/dL. The formal concentrations of the Nova Linearity solutions are as 
follows: L1=0.30-0.80 mg/dL, L2=0.80-1.50 mg/dL, L3=1.70-2.50 mg/dL, L4=4.00-
7.00 mg/dL, L5=7.00-12.00 mg/dL. 
 
Opened Bottle Stability: According to the sponsor, the Linearity and Control solutions 
are stable for up to 5 weeks after date of opening, when stored at 2-8 ⁰C. It was stated 
that stability up to 5 weeks is also viable when the solutions are stored at 25 ⁰C.This 
was demonstrated in real time studies. It was found that all analytes satisfied the 
sponsor’s acceptance criteria of +/-15 %, (for L1) and +/-10 % (for all other levels) 
deviation from analyte concentration at day 0. 
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Closed Bottle Stability (Shelf Life): According to the sponsor, the shelf life of the 
solutions are stable for up to two years from the date of manufacture, when stored at 
2-8 ⁰C. All analytes were tested at temperatures of 5, 25, 40, and 50 ⁰C for 9 weeks in 
order to predict the two year stability, when the analytes are stored at 2-8 ⁰C. The 
percentage loss of stability was determined in comparison to Day Zero values. The 
product is considered to be stable when the reported loss is less than or equal to 15 %. 
All analytes met the sponsor’s acceptance criteria, therefore verifying the closed bottle 
stability claim. Real time studies are still being conducted. 
 
iv) Detection limit 
The Nova StatSensor-i Creatinine Meter detection limit was assessed by following the 
Nova Biomedical Co.’s protocol, which was developed according to CLSI-EP17-A 
(Interference Testing in Clinical Chemistry). The limitation of Blank (LoB) was 
determined to be 0.055 g/dL and the Limit of Detection (LoD) was determined to be 
0.124 mg/dL. 
 
v) Analytical specificity 
Interference studies were carried out based on the CLSI EP7-P (Interference Testing 
in Clinical Chemistry). The studies involved several compounds which were used to 
determine if their presence affected the creatinine in whole blood reporting. The studies 
were carried out where three whole blood samples were prepared with target ranges 
of 0.5 - 1.5, 2.0 - 4.0, and 6.0 - 10.0 mg/dL. The above mentioned compounds were 
added in four different concentrations and three samples were run for each of these 
concentrations. The sponsor defined non-interference as ≤ 15 % for the target range 
0.3 - 1.5 mg/dL and ≤ 10 % for the target ranges > 1.5 mg/dL.  
The following compounds produced no interference at the relevant concentrations: 
Acetaminophen 10 mg/dL, Ascorbic Acid 3.5 mg/dL, Bilirubin 15 mg/dL, Cholesterol 
1000 mg/dL, Creatine 4 mg/dL, L-Dopa 0.3 mg/dL, Dopamine 10 mg/dL, Glucose 
500 mg/dL, Heparin 120 U/dL, Maltose 100 mg/dL, Triglyceride 1000 mg/dL, Uric Acid 
20 mg/dL, and Haemoglobin up to 2.6 g/dL.  
 
Hematocrit studies were conducted in order to determine the effect of varying levels 
hematocrit on creatinine results that were determined by the Nova StatSensor. Blood 
samples were prepared and spiked at three different levels of hematocrit, 28, 43, 59 %, 
and five different creatinine concentrations, 0.3 - 1.5, 1.5 - 3.0, 3.0 - 6.0, 6.0 - 9.0, and 
9.0 - 12.0 mg/dL. The sponsor again defined non-interference as ≤ 15% for the target 
range 0.3 - 1.5 mg/dL and ≤ 10 % for the target ranges > 1.5 mg/dL. The performance 
of the Nova StatSensor at hematocrit concentrations of 30 – 60 % were defined as 
acceptable. 
 
Evaluation of humidity and temperature was conducted using whole blood with three 
creatinine target concentrations. Nova StatSensor meters were placed in 
environmental chambers at varying humidity and temperature in order to determine 
the effects of such environmental conditions on the Nova StatSensor Creatinine 
device. The sponsor defined non-interference as ≤ 15 % for the target range 0.3 - 
1.5 mg/dL and ≤ 10 % for the target ranges > 1.5 mg/dL. The Nova StatSensor met 
the specified criteria when exposed to a temperature range of 15 – 40 ⁰C and a 
humidity range of 20 – 80 %. 
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vi) Assay cut-off 
Not applicable. 
 
2.4.2 Comparison studies 
i) Method comparison with predictive device 
Five external Point of Care sites were used to carry out method comparisons, where 
typical Point of Care staff were untrained in the use of the Nova StatSensor device. 
Whole blood venous, arterial, and capillary samples were collected at each of the sites 
and compared against the predicate devices listed in Table 4.  
The samples were endogenous and compared across the measuring range indicated 
below. There was no significant difference in results across the various sites.  
The results were pooled for venous, arterial, and capillary.  
Y = 0.9873 x + 0.0241         
 (2.8) 
r² = 0.9858           
 (2.9) 
n = 947           
 (2.10) 
Range = 0.3 – 12.9 mg/dL         
 (2.11) 
  
ii) Matrix comparison 
The Nova StatSensor Creatinine Hospital Meter is designed for measurement of 
creatinine within the matrix of whole blood only. A comparison study was carried out 
where whole blood samples, venous, arterial, and capillary origins, were compared 
against serum samples, during method comparison.  
Samples were again compared against the predicate devices on whole blood samples. 
Samples were again endogenous and compared across the measuring range as 
stated below. It must be noted that these samples were the same samples used for 
the above method comparison study. 
 
Venous Blood    
Y = 0.9896 x + 0.0244        
 (2.12)  
r² = 0.9783          
 (2.13)  
n = 722          
 (2.14)  
Range = 0.30 – 10.8 mg/dL        
 (2.15) 
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Arterial Blood 
Y = 0.9792 x + 0.0787        
 (2.16) 
r² = 0.9946           
 (2.17) 
n = 76            
 (2.18) 
Range = 0.57 – 12.0 mg/dL         
 (2.19) 
 
Capillary Blood 
Y = 0.9851 x + 0.0031         
 (2.20) 
r² = 0.9829           
 (2.21) 
n = 149           
 (2.22) 
Range = 0.40 – 12.9 mg/dL         
 (2.23) 
 
 
2.4.3 Clinical studies 
i) Clinical Sensitivity 
Not applicable. 
 
ii) Clinical specificity 
Not applicable. 
 
iii) Other clinical supportive data (when a. and b. are not applicable) 
Not applicable. 
 
2.4.3 Clinical cut-off 
Not Applicable. 
 
2.4.4 Expected values/Reference range 
Normal Creatinine value is less than 1.2 mg/dL 
The sponsor referenced: Burtis, Carl A & Ashwood, Edward. 1999. Tietz Textbook of 
Clinical Chemistry. 
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APPENDIX C- SOPs 
 
Screening for Chronic Kidney Disease (CKD) in a high risk population using a Point of 
Care Instrument for creatinine measurement – a community based study (The Bellville 
South Africa Study) 
 
STANDARD OPERATING PROCEDURE 1 
 
Title:  Procedure for performing quality control testing 
Analyzer: NOVA StatSensor-i Creatinine Meter 
Written by: Tammy Krige (Dr Megan Rensburg) 
Date:  1 June 2016 
 
1. Purpose: 
 
This operational procedure describes the correct way to perform quality control testing on the 
NOVA StatSensor-i Creatinine Meter using point of care test cartridges to ensure optimum 
operation. The operational procedures are based on information obtained from the NOVA 
StatSensor-i Creatinine Meter Quick Reference Guide and the NOVA StatSensor-i Creatinine 
Control Solution inserts. 
2. Scope: 
 
This procedure is aimed at all trained and certified operators of the NOVA StatSensor-i 
Creatinine Meter. Quality control testing using the NOVA StatSensor-i Creatinine Control 
should be done to confirm that your NOVA StatSensor-i Creatinine Meter System is working 
properly and provides reliable results. Only when controls are used routinely and the values 
obtained are within acceptable ranges can accurate results for patient samples be assured. 
 
3. Reagents, Equipment and Material 
 
 NOVA StatSensor-i Creatinine Meter  
 NOVA StatSensor-i Creatinine Test Strips REF 43272 
 NOVA StatSensor-i Creatinine Control 1 Solution REF 43921 
 NOVA StatSensor-i Creatinine Control 3 Solution REF 43923 
 NOVA StatSensor-i Creatinine QC Log Sheet 
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4. Warnings and Precautions 
 
 For in vitro diagnostic use. 
 Use only the StatSensor Creatinine Control Solution for testing with the Creatinine 
Meter and Statsensor Creatinine Test Strips. 
 Proper handling and disposal methods should be followed in accordance with local, 
state regulations. 
 Use personal protective equipment. 
 Do not use the StatSensor-i controls after their expiration date or if they have not been 
stored in accordance with recommendations. 
 Use for only 90 days after first opening. 
 Discard the vial if there is evidence of microbial or fungal contamination. 
 Do not consume the control solution. If swallowed, seek immediate medical attention. 
 
5. Storage Instructions 
 
 The expiration date of the kit only applies if the product is stored at 2-8ºC in the original 
container. The expiration date is the last day of the month stated on the outer container 
and vial label. 
 Avoid exposure to direct sunlight and temperatures above 30ºC. 
 Do not freeze. 
 
Unopened control vials 
 
 Unopened control vials are stable until expiration date indicated on the vial label when 
stored refrigerated 2-8ºC. 
 
Opened control vials 
 
 Opened controls stable for 90 days after opening when stored at 2-8 ºC. 
 It is recommended to note the date of opening and the new expiry date on the vial 
label. 
 Replace the cap immediately after use. 
 Always store the control vials refrigerated 2-8oC when not in use, with cap tightly 
closed. 
 Opened control vials should be stored in an upright position. 
 
6. Analyzing a Control 
It is recommended to keep a permanent record of all quality control results on the NOVA 
StatSensor-i Creatinine QC Log Sheet. The StatSensor-i Creatinine Meter automatically 
stores the control results in a separate record. Consult the StatSensor-i Creatinine Meter 
User Manual.  
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6.1. Frequency of control testing Controls should be analyzed: 
 Every day prior to study sample collection. 
 With each new shipment of StatSensor-i Creatinine test kits. 
 With each new lot of StatSensor-i Creatinine test kits. 
 At least every 30 days. 
 When training new operators in correct use of the StatSensor-i Creatinine test kit and 
StatSensor-i Creatinine Meter. 
 Anytime an unexpected test result is obtained. 
 
 
6.2. Test Procedure 
Consult the StatSensor-i Creatinine Meter User Manual for information related to the general 
operation of the Meter and StatSensor-i Tetst Strips handling. 
 Control material can be used directly from storage at 2 to 8 ºC.  
 Mix the control material thoroughly by gently inverting the vial several times, avoid 
bubble formation.  
 Wipe away the first drop of control solution using paper towel. 
 Insert Test Strip into the Meter and complete set up steps. 
 Collect a sample using the StatSensor-i Creatinine Test Strip in the Meter. The sample 
can be extracted by droppping the solution directly onto the Test Strip. 
 Clean the outside of the control vial neck and replace the cap tightly. 
 Immediately return the control vial back to the refrigerator after use. 
A detailed, illustrated instruction on how to analyze a control sample is provided in the 
StatSensor-i Creatinine Quick Reference Guide. 
6.3. What do I do if StatSensor-i Creatinine Control results are not within the 
acceptable range?  
 Do not analyze any patient samples.  
 Check the control vial label to make sure it is not expired. 
 Ensure that the control has not been used for more than 90 days.  
 Verify that the controls and test cartridges have been stored correctly. 
 Verify that there is no visual sign of bacterial or fungal growth in the control vial. 
 Correct any procedural error. Re-test the control.  
 If the control values are still not within acceptable range, repeat the test using a new 
vial of control. If the control results are still not acceptable, call Technical Support. 
 
7. References 
 
1. StatSensor-i Creatinine Hospital Meter. Nova Biomedical. Quick Reference Guide. 
2. StatSensor-i Creatinine Control package insert. 
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STANDARD OPERATING PROCEDURE 2 
 
Title:  Patient preparation and taking a finger stick sample 
Written by: RT Erasmus 
Date:  1 June 2016 
 
1. Purpose:  
 This SOP describes the procedure before a blood sample (finger stick) is taken as 
 well as the procedure for taking a finger stick sample 
2. Scope: 
Though this procedure is aimed at all trained and certified operators of the NOVA 
StatSensor-i Creatinine POCT Meter but can be applied to any point of care test 
 
3. Procedure: 
a. Explain procedure to patient (see below)  
b. Informed consent is required for this procedure. Subject should sign the 
form 
c. Infection Control: Gloves should be worn as for handling blood products 
(see also safety SOP) 
 Safe disposal of lancets – should go into sharps bin. 
 Safe disposal of test strips – should go into clinical waste bin.  
 There should be no blood stained equipment in workstation & the only 
reason for this is if staff are placing used equipment in workstation 
following a test. 
 Staff will be audited on this so any blood stained equipment should be 
cleaned or replaced as appropriate. 
 Handwashing: To prevent contamination of the blood sample, both nurse 
& patients hands  should be washed in soap & water rinsed & dried 
thoroughly. Or alternatively plain tap water.  
 Do not use alcohol wipes/gel as can cause inaccurate results. 
 There should be no food, fruit juice, newspaper print, perfumes, hand 
creams, Glossy magazines (paper contains glycerine), hairspray, hair gel. 
d. Taking a blood sample 
Supplies: The following should have been assembled on a tray prior to taking 
the sample: 
 Microtainers 
 Retractable lancets 
 Gauze pad or cotton ball 
 Tape (Band Aid) 
 Sharps Container 
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Lancets 
Various devices for skin puncture are available.  Refer to the manufacturer’s 
directions for optimum performance. 
Patient identification- Testing personnel must positively identify the patient that is 
being drawn.  The following steps ensure patient identification: 
 a. Ask the patient to state their full name, including the spelling of an unusual name. 
If the patient is very young, ask his/her parents or guardian to state the name and/or 
the correct spelling.   
b. Compare the name with that on the patient chart you have. 
Joint Commission: “Use at least two ways to identify patients. For example, use the 
patient’s name and date of birth. This is done to make sure that each patient gets the 
correct medicine and treatment.” 
Fasting Status:  Determine whether the patient has fasted (if necessary) and record 
if necessary (notes column). Some tests require the patient to fast or to eliminate 
certain foods from the diet before the blood drawing.  Time and diet restrictions vary 
according to the tests.  Such restrictions are needed to ensure accurate results. 
 Allergies: Verify that the patient is free of latex allergies if a latex glove is worn 
 Wash your hands, dry them and put on gloves. 
Subject Preparation 
 Reassuring the Patient 
Testing personnel must gain the patient’s confidence and assure him that although 
the puncture will be slightly painful, it will be of short duration.  Patients should never 
be told that “this will not hurt,” and they should be told when the lancet enters the skin 
so as to avoid fright. 
Ensure subject is comfortable and that the subject is ready to proceed. Advise 
subject not to withdraw their hand suddenly when the lancet is applied. Ensure 
subject’s hand is warm. Subject may wash hands using warm water or exercise hand 
to increase blood flow. 
Position subject as either sitting or lying down. The hand from which a specimen is to 
be collected should be below the level of a subject’s heart. 
 
To collect any blood spillage, place small disposable sheet underneath subject’s 
forearm on the side chosen for taking fingerprick specimen.Place lancets and plastic 
mini-pipette on clean dry surface next to subject’s hand with appropriate biohazard 
sharps disposal bin within easy reach. 
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 Procedure for Fingerstick 
Sites for Lancing: Avoid using index finger & thumb as they are used for fine motor 
movements. Lance sides of fingers – not pad or tip. Explain if patient was to become 
visually impaired using the pad could affect their ability to read Braille & more painful 
in pad. Lancet no lower than nail bed avoiding edge of nail. Always rotate sites to 
prevent sore areas. 
a. Clean the chosen puncture site and allow the site to thoroughly dry.  Perform 
the puncture on the centre of the palmer surface the finger- not at the side or 
tip of the finger (check), because the tissue on the side and tip of the finger is 
about half as thick as the tissue in the centre of the finger.  
b. The middle finger and ring finger are the preferred site. The fifth finger must not 
be punctured, because the skin is too thin.  Avoid a finger that is cold, cyanotic 
(blue), swollen, or inflamed. 
c. Position subject so that the finger is steady and supported in a comfortable 
position. 
d. With your thumb and index finger, grasp the patient’s finger between 6 -8 cm 
from the tip of the finger. 
e. With your other hand, hold the sides of the patient’s finger. 
f. Moving your supporting hand toward the tip of the patient’s finger. Apply a 
massaging motion to the fleshy portion of the finger. 
g. Repeat this massaging process five or six times. 
h. Clean the chosen puncture site and allow the site to thoroughly dry. 
i. Select the appropriate retractable lancet, position it above the selected site, 
and activate. Discard of used lancet in approved puncture-resistant sharps 
container. 
j. Puncture sites should be oriented perpendicular to the lines of the fingerprint 
(across the fingerprint). 
k. If the cut is made across the fingerprints and the area has been wiped dry, the 
blood should well up into a large rounded drop.  (If the cut has been made along 
the lines of the fingerprint, the blood will stream down the finger). 
l. After the chosen site has been prepared and punctured, the first drop of blood 
should be wiped away with a gauze pad, since the first drop is most likely to 
contain excess tissue fluid.  Discard of gauze in a biohazard container. 
m. If blood does not flow freely, increase blood flow by holding the finger 
downward and applying gentle continuous pressure above the puncture site.  
Do not massage the area since this may contaminate the blood sample with 
tissue fluid. 
n. Wipe away first drop of blood with sterile gauze pad. Hold finger lower than 
elbow and apply gentle, intermittent pressure. 
o. If blood does not flow easily after gentle pressure, make another puncture using 
a new sterile lancet. 
p. Fill the testing device as needed by gently scooping up the drops of blood and 
allowing them to roll into the container. 
q. Drops of blood should be allowed to flow freely. 
r. After blood has been collected from the patient’s finger, place a piece of gauze 
on the site and apply gentle pressure to stop the blood flow.   
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s. Apply tape to puncture site after bleeding has stopped. Subject may also be 
asked to apply gentle pressure 
t. Remove gloves and wash hands.   
u. Dispose of lancet immediately in biohazard sharps container. Discard gloves, , 
and other used materials in their appropriate containers.        
 Additional Considerations 
Blood should not be taken from swollen or previously punctured site, because 
accumulated  tissue fluid will contaminate the blood specimen. 
 References 
o NCCLS Procedures and Devices for the Collection of Diagnostic Blood 
Specimens by Skin  Puncture; Approved Standard- Fourth Edition, 
September 1999 
o NCCLS Specimen Collection 1989. 6.14-3. 
o Blumenfeld, TA: Clinical Application of Microchemistry.  In Werner M(ed): 
Micro-Techniques  for the Clinical Laboratory: Concept and Application, pp 
1-15.  New York, John Wiley & Sons,  1976. 
o Blumenfeld TA, Hertelendy WG, Ford SH: Simultaneously Obtained Skin 
Puncture Serum, Kin  Puncture Plasma and Venous Serum compared and 
Effects of Warming the Skin Before  Puncture.  Clinical Chemistry 23: 1705, 
1977. 
o Alreja G, Setia N, Nichols J, Pantanowitz L. Reducing patient identification 
errors related to  glucose point- of-care testing. J Pathol Inform 2011; 2: 
22 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097526/] 
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STANDARD OPERATING PROCEDURE 3 
 
Title:  Storage and Stability 
Analyzer: NOVA StatSensor-i Creatinine Meter 
Written by: Tammy Krige (Dr Megan Rensburg) 
Date:  1 June 2016 
 
8. Purpose: 
 
This operational procedure describes the storage and stability of the NOVA StatSensor-i 
Creatinine Meter point of care Test Strips to ensure optimum operation. The operational 
procedures are based on information obtained from the NOVA StatSensor-i Creatinine 
Controls package inserts. 
 
9. Scope: 
 
This procedure is aimed at all trained and certified operators of the NOVA StatSensor-i 
Creatinine Meter. 
 
10. Reagents, Equipment and Material 
 
 NOVA StatSensor-i Creatinine Meter  
 NOVA StatSensor-i Creatinine Test Strips REF 43272 
 NOVA StatSensor-i Creatinine Control 1 REF 43921 
 NOVA StatSensor-i Creatinine Control 3 REF 43923  
 
Storage and Stability 
 
10.1. StatSensor-i Creatinine Meter 
 
Desktop/handheld use 
 
 Store the NOVA StatSensor-i Creatinine Meter on a dry, clean, stable and horizontal 
surface. 
 Empty the Test Strip chamber for storage. 
 Store away from: 
o Condensing humidity and water 
o Heat and large temperature variations 
o Direct sunlight 
o Vibrations (e.g. from centrifuges and dishwashers) 
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Transportation 
 
 Store the NOVA StatSensor-i Creatinine Meter in the original packaging. 
 Ensure the StatSensor-i Creatinine Meter unit includes: 
o StatSensor-i Creatinine Meter  
o Power cable and cord adapter 
o Quick Guides for the available StatSensor-i Creatinine Tests 
o User Manual 
 
10.2. StatSensor-i Creatinine Test Strips REF 43272  
 
Refrigerated Storage: 2- 8 oC 
 
 The StatSensor-i Creatinine Test Strips are stable until the expiry date (12 months) 
only when stored refrigerated in original sealed plastic containers and unopened. 
 The expiry date is the last day of the month stated on the container and packaging 
box. 
 The StatSensor-i Creatinine Test Strips must reach an operating ROOM temperature 
of +/- 25 °C before use. 
 Upon removal from refrigerated storage, leave the Test Strips in the capped container, 
preferably overnight. 
 Do not freeze. 
 
Room Temperature Storage: 15 – 25 oC 
 StatSensor-i Creatinine Test Strips are stable for up to 90 days or until the 
expiration date, whichever comes first. 
 Once opened, keep tightly sealed in original storage container. 
 Avoid exposure to direct sunlight. 
 
10.3. StatSensor-i Creatinine Control Solutions REF 43921 and REF 43923 
 
 The expiration date of the kit only applies if the product is stored at 2-8 ºC in the original 
container. 
 The expiration date is the last day of the month stated on the outer container and vial 
label. 
 Avoid exposure to direct sunlight and temperatures above 30 ºC. 
 Do not freeze. 
 Can be used for running QC straight out of the fridge. 
 
Unopened control vials 
 
 Unopened control vials are stable until expiration date (period of up to 12 months) 
indicated on the vial label when stored refrigerated 2-8 ºC. 
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Opened control vials 
 
 Opened control vials are stable for 90 days when stored refrigerated 2-8 oC. 
 It is recommended to note the date of opening and the new expiry date on the vial 
label. 
 Replace the cap tightly immediately after use. 
 Always store the control vials refrigerated 2-8 oC when not in use. 
 Opened control vials should be stored in an upright position. 
 
11. References 
 
1. NOVA StatSensor-i Creatinine Hospital Meter. Nova Biomedical. Quick Reference Guide. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
75 
 
 
 
STANDARD OPERATING PROCEDURE 4 
 
Title:  Troubleshooting 
Analyzer: NOVA StatSensor-i Creatinine Meter 
Written by: Tammy Krige (Dr Megan Rensburg) 
Date:  1 June 2016 
 
1. Purpose:  
 
This operational procedure provides information on how to troubleshoot when errors codes 
are displayed on the NOVA StatSensor-i Creatinine Meter Analyzer whilst operating the 
instrument. 
 
2. Scope: 
 
This procedure is aimed at all trained and certified operators of the NOVA StatSensor-i 
Creatinine Meter. 
 
3. TROUBLESHOOTING ERROR CODES 
 
An Error Code message with a description of the problem will be on display if an operational 
or system problem occurs. 
 
A few examples of an Error code: 
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Refer to the NOVA StatSensor-i Creatinine Meter Quick Reference Guide Information codes 
and troubleshooting page 30-37. 
If you are still encountering error codes after implementing the corrective action contact the 
following persons:  
 NOVA (Brendan Freitag -  
 Project leaders 
o Prof RT Erasmus   
o Dr M A Rensburg   
 
 
4. References 
 
1. Quick Reference Guide. nova biomedical. Statsensor-i Creatinine HOspital Meter. 
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STANDARD OPERATING PROCEDURE 5 
 
Title:  Cleaning and Maintenance Procedure 
Analyzer: NOVA StatSensor-i Creatinine Meter 
Written by: Tammy Krige (Dr Megan Rensburg) 
Date:  1 June 2016 
 
5. Purpose:  
 
This operational procedure describes how to maintain the NOVA StatSensor-i Creatinine 
Meter to ensure optimum operation. The operational procedures are based on information 
obtained from the NOVA StatSensor-i Creatinine Meter User Manual. 
 
6. Scope: 
 
This procedure is aimed at all trained and certified operators of the NOVA StatSensor-i 
Creatinine Meter. 
 
7. Reagents, Equipment, Material 
 
 NOVA StatSensor-i Creatinine Meter. 
 Disinfectant 
 
8. Maintenance Procedures: 
 
No maintenance of NOVA StatSensor-i Creatinine Meter is required other than cleaning the 
exterior, as well as charging and changing the battery. 
 
 
Cleaning the exterior 
 Cleaning the exterior of the NOVA StatSensor-i Creatinine Meter should be performed 
whenever necessary. Most spills and stains can be removed with water or a mild 
detergent. Power off the Meter while cleaning. 
 Clean the outside of the Analyzer and the touch display with a clean, non-abrasive 
cloth dampened in water, or detergent, to remove any spills or dirt marks. 
 To disinfect the exterior of the instrument, use any of the following: Dilute bleach (10% 
solution of household bleach, Sodium Hypochlorite), 70% isopropyl alcohol. Avoid 
benzene and strong acids. 
 Using any of the above, dampen the cloth and wipe down the Meter surfaces. 
 Wipe dry immediately. 
 Power on the Meter. 
NOTE: Never immerse the device. Never spray the device with disinfectant. 
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Charging and changing the battery pack: 
Docking/Charging Station: 
 When the meter is not in use, store it in the docking/charging station. This enables the 
meter to remain fully charged and connected to the computer network.  
 When the battery is LOW symbol displays on the screen, place the device into the 
docking/charging station. If you have a spare fully charged battery, change with the 
low battery. 
NOTE: The left, green light is on if the station is connected to the network. The middle, green 
light is on if data is transferring. The right light is green for fully charged, or yellow for charging. 
Changing the battery: 
If you have a spare, fully charged battery it can be changed with the drained battery to allow 
for continuous use of the Meter. 
WARNING: Replace the drained battery with NOVA P/N 46827 ONLY. Using another battery 
may present a risk of fire or explosion. If discarding, dispose of battery promptly. Keep away 
from children. 
Instructions: 
 Press the power button to enter “Sleep Mode”, allowing for 20 seconds to change the 
battery without losing date/time settings. (If it takes longer than 20 seconds of changing 
the battery, then power up the Meter again and re - login, and set date and times. 
 To release battery cover, push down on the two cover latches. Remove the cover. 
 Push down on the battery latch to remove the drained battery. 
 Replace with a fully charged battery by insertion from bottom first, then push in the top 
of the battery.  
 Replace the battery cover and dock the meter into the charging station before use.  
 Replace the drained battery into the separate charging station.  
 
9. Safety precautions 
 
Recommended to use gloves when handling any potentially biohazardous material and 
adherence to general principles of health and safety precautions should be followed.  
 
10. References 
 
1. StatSensor-i Creatinine Hospital Meter. Nova Biomedical. Quick Reference Guide. 
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STANDARD OPERATING PROCEDURE 6 
 
Title:  Safety Procedure 
Written by: RT Erasmus 
Date:  1 June 2016 
 
1. Purpose:  
 To describe safety procedures to be carried out before and after taking blood 
samples 
2. Scope: 
 This procedure is aimed at all trained and certified operators of the Nove 
StatSensor-i Creatinine Meter. It also applies to all Point of Care Instruments and 
Collecting Devices 
 
3. General Information: 
 POC devices pose a risk of transmitting infectious organisms 
Reagents and carriers besides the devices can also transmit infectious organisms. 
 
4. Health and safety : 
Universal precautions must be observed when collecting blood specimens. All 
samples should be handled as potentially infectious for HIV, Hep B and other 
pathogens. 
 Check the following: 
 Hand washing facilities and soap should be available 
 Disinfectants should be available for any spillage 
 Eye decontamination station should be available 
  GLOVES SHOULD ALWAYS BE WORN WHEN HANDLING BLOOD SPECIMENS 
i. Prepare the equipment on the clinical workspace before the subject enters the 
room. 
ii. Ensure the clinical waste bin and sharps bin are readily available for point of 
generation disposal. 
iii. Wash hands and don gloves and goggles 
iv. Perform procedure as per clinical guidelines 
v. Dispose of sharps and clinical waste at point of generation into properly labelled 
or colour-coded sharps containers and biohazard trash bags and bins. 
vi. Eating, drinking, or applying makeup in areas where specimens are collected and 
where testing is being performed is prohibited  
vii. Instrument may require to be disinfected (check guidelines) 
 
  
Stellenbosch University  https://scholar.sun.ac.za
80 
 
 
 
Patient Safety 
 Reassure patient. 
 Explain procedure 
 Do not share lancets between patients 
 Check for bleeding and ensure that bleeding has stopped before patient 
leaves the room 
 All sharps and strips etc to be disposed before the next patient presents 
 Disinfect area if there is any contact with blood products 
 
CONSULT THE FOLLOWING 
 A written plan for exposure control, including post-exposure evaluation and follow-
up for the employee in the event of an "exposure incident;"  
 Use of Universal Precautions, an approach to infection control in which all human 
blood and certain human body fluids are treated as if known to be infectious for 
HIV, hepatitis B virus, hepatitis C virus, and other blood borne pathogens. 
Universal Precautions is one component of Standard Precautions, a broader 
approach designed to reduce the risk for transmission of microorganisms from both 
recognized and unrecognized sources of infection in hospitals  
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